Exclusive: Counter Extremism Group says outward rejection of violence is 'increasing the potential for radicalisation'
Reported by Independent 12 hours ago.
Far-right groups across Europe 'using Islamist techniques' to recruit followers, report says
↧
↧
ROBERT TOMBS on how the French protests are a warning to Europe
Now, once again, France’s rulers have been taken by surprise and all they can do is call out the riot squads. What began as a protest against fuel taxes has turned into a general movement of frustration.
Reported by MailOnline 9 hours ago.
↧
They survived the Holocaust. Must they go back into hiding?
NEW YORK - They survived the Europe of the Holocaust. But a recent rise in anti-Semitic acts in the United States has rekindled old fears: Should they again go into hiding, or should they instead reach out to share their experiences?
Reported by Bangkok Post 8 hours ago.
↧
Seven of the best Porsches of the last 70 years
To mark seven decades of Porsche, we pick our best of a celestial breed
The first Porsche was built in 1948 in a collection of sheds on the site of a former sawmill in a place called Gmund, in Austria. Its designer had recently been released from prison where he had been interned by the Allies. The car had more than a passing resemblance to the Volkswagen Beetle – and with good reason, for the same man had designed both.
He was called Ferdinand Porsche. All its moving parts – engine, brakes, suspension and steering – were either lifted directly or derived from Beetle running gear and despite the engine being given a fairly monumental tuning upgrade, the 1.1-litre flat four still only generated, wait for it, 40bhp.
It is fair to say Porsche has come some distance in the past 70 years. During that time the car maker has become the most profitable on earth, and its sphere of operation is now so wide that it makes everything from hypercars to SUVs. It has won in Formula 1 and amassed an unrivalled 19 victories at Le Mans. Today those SUVs are the most coveted cars of their kind, yet Porsche has not forgotten its roots: it still makes a flat four open two-seater with its engine located behind the driver, just like that first 356 all those years ago.
So to celebrate we thought we’d look at some of the very greatest (and just a few of the not so great) cars that brought Porsche from some huts in Austria to becoming the most successful manufacturer of sporting cars the world has yet known.
*1948-58*
*1954 356 Speedster*
Six years into the story of Porsche and the little company was growing fast. Its success was built on the reputation of Ferdinand Porsche as one of Europe’s pre-eminent automotive engineers, and the vision of his son, Ferry, who saw a clear gap in the market for a super-high-quality sporting car that could be used not merely as recreation but as daily transport, too. The essential rightness of that idea can be seen in the fact that much the same thing can be said about a 2018 911.
But Porsches were expensive – too expensive for some tastes in the largest market of all on the other side of the Atlantic. Why buy a Porsche with a small pushrod four-cylinder engine when you could buy a Jaguar with a twin-cam six of over double the capacity and which came complete with Le Mans-winning pedigree?
But it wasn’t Porsche who spotted the need for something more affordable that would also add some spice to the Porsche proposition, and it wasn’t Porsche that came up with the solution. It was a chap called Max Hoffman, who imported Porsches into the US (he also persuaded Mercedes-Benz to create the 300SL ‘Gullwing’ and inadvertently invented the supercar). Hoffman convinced Porsche that a stripped-out, lightweight, more affordable 356 would not only sell in its own right but also, by taking advantage of the burgeoning club racing scene, sprinkle some much-needed stardust on Porsche as a whole The fact that a certain James Dean owned and raced one probably helped, too.
So the 356 Speedster, with its steeply raked and detachable windscreen, was born. It was Porsche’s fastest road car to date and the best to drive. But it also looked incredible and Hoffman had to beg Stuttgart to send him more. A flame had been lit, and in cars like the 911 GT3 RS, it burns to this day
*1958-68*
*1966 911S*
It has to be a 911, but which one? The 1963 original, the car that was meant to be called the 901 until Peugeot got shirty and asserted its rights to triple-digit car names with a zero in the middle? Or maybe the 1967 911R, the first factory-built racing 911, to date still the lightest 911 and the car that won the 84-hour 1967 Marathon de la Route at the Nurbürgring?
I’m going for a standard 911S of 1966, the most highly developed road-going 911 until they stretched its wheelbase in 1968 to try to calm its handling. This car holds the very essence of the 911 spirit: small, light, compact and quick, its little 2.0-litre flat six making an impressive 160bhp which, combined with ridiculous agility, made it far faster point to point than almost anything on the road.
Yes, it could be tricky if you didn’t apply the old ‘slow in, fast out’ rule, but everything about this car, from its hyperactive steering to its one-of-a-kind gearbox, is designed to keep you busy. To me, it’s what a 911 should be all about.
*1968-78*
*1974 911 Turbo*
I’m going to get into trouble for this. Firstly, because I didn’t choose the iconic 911 2.7 Carrera RS of 1973, and second, because while the early 911 Turbo was a great car, it wasn’t necessarily that good. And you’ll never know how close I came to choosing the 928 (which would have been an act of the purest heresy among the rear-engined, aircooled Porsche-bore aficionados).
I chose the Turbo not because it was the first production car to use this means of forced induction (it wasn’t), nor because it was incredibly quick (Boxers and Countachs were quicker), nor because I love the looks (although I do), with those dramatically flared arches and that enormous tail spoiler designed to cool the motor as much as keep the rear end on the deck. No, I chose it because it was born for the purest of reasons – racing – and because, unlike the BMW 2002 Turbo launched at the same time, Porsche stuck with it and turned it into a game-changer. Besides, this story wouldn’t be complete without a tricky 911 in the cast.
And the early Turbo could be properly tricky. It had enormous turbo lag and so much rear grip it understeered everywhere until you did something desperate with the brakes, at which point the back would go in an instant and usually stay gone. It made a worse noise than a 911 and had fewer gears because, said Porsche, it didn’t need five, although the fact that the internals needed such strengthening that there wasn’t room for more than four probably had rather more to do with it.
But it contained technology invented for the 1100bhp Porsche 917/30 and would in time turn into the Le Mans-winning 935, one of the maddest racers ever made. It also began a tradition of 911 Turbos, one of the finest in Porsche’s pantheon.
*1978-88*
*1987 Porsche 959*
I would argue that the 959 was the first hypercar. It was a car not only faster than anything else to wear a number plate but also one whose speed was achieved through technology so sophisticated that it made the next-best effort look like something cobbled together by Hagar the Horrible. The fastest Ferraris and Lamborghinis subjected to independent testing ran out of puff in the mid-180s bracket. The 959 did 197mph.
It might have looked like a melted 911 but only its roof, glass and doors were carried over. The rest was crafted from Kevlar, Nomex and aluminium. Its shape generated no lift, a unique achievement at the time, while its engine was derived from a Le Mans winner, with an air-cooled block but water-cooled heads and sequential turbocharging. It had a six-speed gearbox, double-wishbone suspension, ABS, adjustable dampers, four-wheel drive with a variable front-to-rear torque split, bespoke tyres and driver-selectable terrain control. Thirty years ago, it was science fiction made fact.
The result was not just a great Porsche but also one of the greatest and most important high-performance road cars in history. Within that stunning shape lie lessons that continue to inform the industry to this day.
*1988-98*
*1994 968 Clubsport*
Got to have something with an engine in its nose? Then what better than this? Actually its philosophy was similar to that of the 356 Speedster from 40 years earlier: in short, to save a little money by losing some equipment. The result is not just cheaper but also lighter and better to drive.
So good to drive, in fact, that I’ve always suspected the ClubSport (or Clubbie as it was known at Autocar) to be one of those happy cars that turned out to be even more enjoyable than its creators intended. Few cars have ever been so poorly described by specification sheet alone. And quick though it was, it was never really that quick, and nor did it need to be. When I think of it, it is not words like power, grip and pace that come to mind, but ones rather more descriptively enticing, like poise, feel and balance. This was a supremely tactile car with a genius for inspiring love in everyone from novices to professional drivers. It was also the last normally aspirated four-cylinder car that Porsche would make
*1998-2008*
*2001 Cayenne*
Now this really is sacrilegious. I only have seven Porsches and I go and choose this hideous SUV with no more in common with the svelte grace of the cars on which Porsche built its reputation than do I with Audrey Hepburn. Allow me to explain myself.
I think we can agree that the Cayenne was an important car. It is well known that Porsche was nearly bankrupt in the mid 1990s, and while the Boxster and 996-generation 911 steadied the ship, it was the Cayenne that steered it towards the enormous profitability the company enjoys today. Soon after it went on sale, it was outselling all other Porsches combined. But even that’s not really why it’s here. I chose it because of all the other wonderful Porsches – the hot 911s, Caymans and Boxsters – that would never have been built without the profit that it and its Macan offspring returned to Stuttgart. Make no mistake, without this blunderbuss of an off-roader, without such a blatant diversion from the comparatively compact, lightweight, simple and sporting path of all previous Porsches, all the compact, lightweight, simple and sporting models that followed it would either have been far less good or simply not existed at all. Love a good GT3? You have the Cayenne to thank for it.
*2008-2013*
*2010 911 GT3 RS*
I wasn’t going to miss a GT car out but the choice is hard. Many are excluded on grounds of age, but why not a modern one? I think the 2017 GT2 RS is one of the most incredible devices of any kind I have driven. Or what about the Cayman GT4, perhaps the sweetest natured of all its brethren? But I can choose but one, and the second generation 997 GT3 RS is it.
It provides the perfect synthesis of involvement, PORSCHE 70 T entertainment and speed while remaining sufficiently quiet and comfortable to fit the 911’s original brief of being civilised enough to use every day. It has the loveliest gearbox ever fitted to a 911 and, in its 450bhp flat six with its Le Mans-winning heritage, a perfect pedigree under the engine cover. It’s a car you want to drive everywhere and whenever you can. And if all that doesn’t make a great Porsche, I have no idea what does.
*Read more*
*The history of the Porsche 911: picture special*
*New 2019 Porsche 911: eighth-generation sports car revealed*
*2020 Porsche 911 GT3 spied in near-production bodywork* Reported by Autocar 5 hours ago.
The first Porsche was built in 1948 in a collection of sheds on the site of a former sawmill in a place called Gmund, in Austria. Its designer had recently been released from prison where he had been interned by the Allies. The car had more than a passing resemblance to the Volkswagen Beetle – and with good reason, for the same man had designed both.
He was called Ferdinand Porsche. All its moving parts – engine, brakes, suspension and steering – were either lifted directly or derived from Beetle running gear and despite the engine being given a fairly monumental tuning upgrade, the 1.1-litre flat four still only generated, wait for it, 40bhp.
It is fair to say Porsche has come some distance in the past 70 years. During that time the car maker has become the most profitable on earth, and its sphere of operation is now so wide that it makes everything from hypercars to SUVs. It has won in Formula 1 and amassed an unrivalled 19 victories at Le Mans. Today those SUVs are the most coveted cars of their kind, yet Porsche has not forgotten its roots: it still makes a flat four open two-seater with its engine located behind the driver, just like that first 356 all those years ago.
So to celebrate we thought we’d look at some of the very greatest (and just a few of the not so great) cars that brought Porsche from some huts in Austria to becoming the most successful manufacturer of sporting cars the world has yet known.
*1948-58*
*1954 356 Speedster*
Six years into the story of Porsche and the little company was growing fast. Its success was built on the reputation of Ferdinand Porsche as one of Europe’s pre-eminent automotive engineers, and the vision of his son, Ferry, who saw a clear gap in the market for a super-high-quality sporting car that could be used not merely as recreation but as daily transport, too. The essential rightness of that idea can be seen in the fact that much the same thing can be said about a 2018 911.
But Porsches were expensive – too expensive for some tastes in the largest market of all on the other side of the Atlantic. Why buy a Porsche with a small pushrod four-cylinder engine when you could buy a Jaguar with a twin-cam six of over double the capacity and which came complete with Le Mans-winning pedigree?
But it wasn’t Porsche who spotted the need for something more affordable that would also add some spice to the Porsche proposition, and it wasn’t Porsche that came up with the solution. It was a chap called Max Hoffman, who imported Porsches into the US (he also persuaded Mercedes-Benz to create the 300SL ‘Gullwing’ and inadvertently invented the supercar). Hoffman convinced Porsche that a stripped-out, lightweight, more affordable 356 would not only sell in its own right but also, by taking advantage of the burgeoning club racing scene, sprinkle some much-needed stardust on Porsche as a whole The fact that a certain James Dean owned and raced one probably helped, too.
So the 356 Speedster, with its steeply raked and detachable windscreen, was born. It was Porsche’s fastest road car to date and the best to drive. But it also looked incredible and Hoffman had to beg Stuttgart to send him more. A flame had been lit, and in cars like the 911 GT3 RS, it burns to this day
*1958-68*
*1966 911S*
It has to be a 911, but which one? The 1963 original, the car that was meant to be called the 901 until Peugeot got shirty and asserted its rights to triple-digit car names with a zero in the middle? Or maybe the 1967 911R, the first factory-built racing 911, to date still the lightest 911 and the car that won the 84-hour 1967 Marathon de la Route at the Nurbürgring?
I’m going for a standard 911S of 1966, the most highly developed road-going 911 until they stretched its wheelbase in 1968 to try to calm its handling. This car holds the very essence of the 911 spirit: small, light, compact and quick, its little 2.0-litre flat six making an impressive 160bhp which, combined with ridiculous agility, made it far faster point to point than almost anything on the road.
Yes, it could be tricky if you didn’t apply the old ‘slow in, fast out’ rule, but everything about this car, from its hyperactive steering to its one-of-a-kind gearbox, is designed to keep you busy. To me, it’s what a 911 should be all about.
*1968-78*
*1974 911 Turbo*
I’m going to get into trouble for this. Firstly, because I didn’t choose the iconic 911 2.7 Carrera RS of 1973, and second, because while the early 911 Turbo was a great car, it wasn’t necessarily that good. And you’ll never know how close I came to choosing the 928 (which would have been an act of the purest heresy among the rear-engined, aircooled Porsche-bore aficionados).
I chose the Turbo not because it was the first production car to use this means of forced induction (it wasn’t), nor because it was incredibly quick (Boxers and Countachs were quicker), nor because I love the looks (although I do), with those dramatically flared arches and that enormous tail spoiler designed to cool the motor as much as keep the rear end on the deck. No, I chose it because it was born for the purest of reasons – racing – and because, unlike the BMW 2002 Turbo launched at the same time, Porsche stuck with it and turned it into a game-changer. Besides, this story wouldn’t be complete without a tricky 911 in the cast.
And the early Turbo could be properly tricky. It had enormous turbo lag and so much rear grip it understeered everywhere until you did something desperate with the brakes, at which point the back would go in an instant and usually stay gone. It made a worse noise than a 911 and had fewer gears because, said Porsche, it didn’t need five, although the fact that the internals needed such strengthening that there wasn’t room for more than four probably had rather more to do with it.
But it contained technology invented for the 1100bhp Porsche 917/30 and would in time turn into the Le Mans-winning 935, one of the maddest racers ever made. It also began a tradition of 911 Turbos, one of the finest in Porsche’s pantheon.
*1978-88*
*1987 Porsche 959*
I would argue that the 959 was the first hypercar. It was a car not only faster than anything else to wear a number plate but also one whose speed was achieved through technology so sophisticated that it made the next-best effort look like something cobbled together by Hagar the Horrible. The fastest Ferraris and Lamborghinis subjected to independent testing ran out of puff in the mid-180s bracket. The 959 did 197mph.
It might have looked like a melted 911 but only its roof, glass and doors were carried over. The rest was crafted from Kevlar, Nomex and aluminium. Its shape generated no lift, a unique achievement at the time, while its engine was derived from a Le Mans winner, with an air-cooled block but water-cooled heads and sequential turbocharging. It had a six-speed gearbox, double-wishbone suspension, ABS, adjustable dampers, four-wheel drive with a variable front-to-rear torque split, bespoke tyres and driver-selectable terrain control. Thirty years ago, it was science fiction made fact.
The result was not just a great Porsche but also one of the greatest and most important high-performance road cars in history. Within that stunning shape lie lessons that continue to inform the industry to this day.
*1988-98*
*1994 968 Clubsport*
Got to have something with an engine in its nose? Then what better than this? Actually its philosophy was similar to that of the 356 Speedster from 40 years earlier: in short, to save a little money by losing some equipment. The result is not just cheaper but also lighter and better to drive.
So good to drive, in fact, that I’ve always suspected the ClubSport (or Clubbie as it was known at Autocar) to be one of those happy cars that turned out to be even more enjoyable than its creators intended. Few cars have ever been so poorly described by specification sheet alone. And quick though it was, it was never really that quick, and nor did it need to be. When I think of it, it is not words like power, grip and pace that come to mind, but ones rather more descriptively enticing, like poise, feel and balance. This was a supremely tactile car with a genius for inspiring love in everyone from novices to professional drivers. It was also the last normally aspirated four-cylinder car that Porsche would make
*1998-2008*
*2001 Cayenne*
Now this really is sacrilegious. I only have seven Porsches and I go and choose this hideous SUV with no more in common with the svelte grace of the cars on which Porsche built its reputation than do I with Audrey Hepburn. Allow me to explain myself.
I think we can agree that the Cayenne was an important car. It is well known that Porsche was nearly bankrupt in the mid 1990s, and while the Boxster and 996-generation 911 steadied the ship, it was the Cayenne that steered it towards the enormous profitability the company enjoys today. Soon after it went on sale, it was outselling all other Porsches combined. But even that’s not really why it’s here. I chose it because of all the other wonderful Porsches – the hot 911s, Caymans and Boxsters – that would never have been built without the profit that it and its Macan offspring returned to Stuttgart. Make no mistake, without this blunderbuss of an off-roader, without such a blatant diversion from the comparatively compact, lightweight, simple and sporting path of all previous Porsches, all the compact, lightweight, simple and sporting models that followed it would either have been far less good or simply not existed at all. Love a good GT3? You have the Cayenne to thank for it.
*2008-2013*
*2010 911 GT3 RS*
I wasn’t going to miss a GT car out but the choice is hard. Many are excluded on grounds of age, but why not a modern one? I think the 2017 GT2 RS is one of the most incredible devices of any kind I have driven. Or what about the Cayman GT4, perhaps the sweetest natured of all its brethren? But I can choose but one, and the second generation 997 GT3 RS is it.
It provides the perfect synthesis of involvement, PORSCHE 70 T entertainment and speed while remaining sufficiently quiet and comfortable to fit the 911’s original brief of being civilised enough to use every day. It has the loveliest gearbox ever fitted to a 911 and, in its 450bhp flat six with its Le Mans-winning heritage, a perfect pedigree under the engine cover. It’s a car you want to drive everywhere and whenever you can. And if all that doesn’t make a great Porsche, I have no idea what does.
*Read more*
*The history of the Porsche 911: picture special*
*New 2019 Porsche 911: eighth-generation sports car revealed*
*2020 Porsche 911 GT3 spied in near-production bodywork* Reported by Autocar 5 hours ago.
↧
Miss Mexico Vanessa Ponce crowned Miss World 2018 in Sanya
SANYA, China, Dec. 9, 2018 /PRNewswire/ -- The 26-year-old Miss Mexico Vanessa Ponce de león became the winner of the Miss World 2018 competition, which was held at the Sanya City Arena in Sanya, China on December 8th, 2018.Miss Thailand Nicolene Pichapa Limsnukan finished the runner-up and Miss Uganda Quiin Abenakyo ranked the third.
"I can't believe it, I really can't believe it... And I think all the girls deserved it. I am proud to represent all of them. I will do as much as I can in the time I have got. Thank you so much, everyone," Vanessa said backstage after winning the crown.
Vanessa completed her Degree in International Business and is currently on the Board of Directors of a Rehab centre for girls and volunteers for 'Migrantes en el Camino'. She is a speaker for the National Youth Institute as well as working as a model and a presenter. Vanessa has qualified as an open water scuba diver; she also enjoys playing volleyball, painting and ultimate Frisbee. Her favourite TV show is 'Downton Abbey'. Personal Motto: 'We all need each other.'
*Miss World Continental Queens 2018 Are:
*Miss World Europe is: Belarus
Miss World Caribbean is: Jamaica
Miss World Americas is: Mexico
Miss World Africa is: Uganda
Miss World Asia and Oceania is: Thailand
The Miss World 2018 pageant was hosted by the Sanya Municipal People's Government and New Silk Road Group.
This was the eighth time that Sanya has hosted the contest (Sanya hosted the Miss World Finals in 2003, 2004, 2005, 2007, 2010, 2015, 2017, and 2018). The Miss World pageant, created in Britain by Eric Morley in 1951, is the oldest surviving major international beauty contest. It is one of the three most publicised beauty contests in the world, alongside the Miss Universe and Miss Earth contests.
View original content:http://www.prnewswire.com/news-releases/miss-mexico-vanessa-ponce-crowned-miss-world-2018-in-sanya-300762328.html Reported by PR Newswire Asia 5 hours ago.
↧
↧
Maurizio Sarri Claims Chelsea Deserved Win in Stunning Victory Over 'Best Team in Europe' Man City
Reported by SI.com 2 hours ago.
↧
Europe’s Socialists choose their leader for May’s Parliamentary elections
Timmermans to lead list after nomination goes unchallenged in Lisbon
Reported by euronews 1 hour ago.
↧
With Brexit Plans in Doubt, Protesters Set to Rally in London
An anti-Islam activist plans to lead a march for a clean split from Europe, while pro-Europe demonstrators will rally to stay in the bloc.
Reported by NYTimes.com 59 minutes ago.
↧
Western Intel Docs Say Iran's Missiles Now Capable of Reaching Europe – Reports
Reported by RIA Nov. 42 minutes ago.
↧
↧
Transfer news LIVE: All the latest from the Premier League and Europe
Speculation is increasing as the New Year grows on the horizon with a number of clubs look to add to their squads. Join Sportsmail for live updates and all the transfer news from across Europe.
Reported by MailOnline 9 minutes ago.
↧
Japan shuns Kagawa for bid to reclaim Asian Cup
Japan dropped former Manchester United star Shinji Kagawa from the Blue Samurai's bid to reclaim the Asian Cup, opting instead for a squad filled with young Europe-based talents.…
Reported by Japan Today 2 hours ago.
↧
Neurovascular Embolectomy Device Market Global Size Worth Around $1.9 Billion By 2025: Acumen Research and Consulting
Neurovascular Embolectomy Device Market (Product: Aspiration Devices, Stent Retrievers) – Global Industry Analysis, Market Size, Opportunities and Forecast, 2018 - 2025
LOS ANGELES, Dec. 12, 2018 (GLOBE NEWSWIRE) -- *Global neurovascular embolectomy device market* is expected to reach the market value of around $1.9 billion by 2025 and is projected to grow at a CAGR of over 17% in terms of revenue during the period 2018 – 2025. Escalating cases of stroke with changing lifestyle and environmental calamities have boosted the demand for neurovascular embolectomy devices. Neurovascular embolectomy device market is driven by increasing cases of strokes, innovation and product development, international trade, and increasing consumer awareness for strokes across the globe. Superior healthcare treatment with better devices that offer improved success rates increases the adoption of neurovascular embolectomy devices. Growing consumer knowledge for post surgery safety has increased the application of apt devices suitable for patients. Hence, rising expenditure capacity and increasing knowledge of consumers are also fueling the demand for neurovascular embolectomy devices. The strengthening economic conditions in different countries, as well suggest decent growth break-through for the stake-holders of neurovascular embolectomy device market.
*Download Report Sample Pages@ https://www.acumenresearchandconsulting.com/request-sample/917 *
The standardization of legal framework by global and regional healthcare organizations and government has generated opportunities for manufacturers to invest in product and market development. Focusing on research & development by government and industry players can take the neurovascular embolectomy device market to sustainable market growth. Moreover, this has paved a way for increased international trade thereby promoting healthy sharing of technology, education, neurological science and quality improvement.
Federal & regulatory body laws and regulations possess to be the prime challenge to the neurovascular embolectomy device market. According to key industrialists and opinion leaders, the norms and procedures for neurovascular embolectomy device research & development and industrial applications have been strictly regulated due to safety concerns. This may affect the demand for both the neurovascular embolectomy device industry and its end-use application. In addition, global downturn and high cost of technology also possesses a potential risk to the growth of the neurovascular embolectomy device market.
*View Detailed Information@ https://www.acumenresearchandconsulting.com/neurovascular-cmbolectomy-device-market *
*Bare Platinum Coils to Aid Growth of Market*
Neurovascular device market has experienced an intense move regarding products and systems. Specialists need to receive instruments and procedures that offer higher window for stroke treatment with high achievement rate and negligible post-surgical effect. This is sustained by the way that interest for uncovered platinum loops is developing at a higher pace in contrast with coated coils. This is mainly because of huge expenses related to coated coils and their less enhanced clinical results contrasted with bare platinum coils. Also, stroke treatment includes high healthcare spending that drives the focus on improvement of efficient treatment strategies.
*Regional Analysis *
Currently, North America is the largest market for neurovascular devices. As per Stroke Association, approximately 1 million Americans each year are affected by stokes. Also, this is one of the leading triggers of disability and death. In the U.S., the financial drain of stroke is valued at around USD 30 billion annually, which includes the expenditure on health care services, prescriptions, and reduced output. The ASA has put up great effort to transform the existing healthcare systems and patients worldwide by collaborating with other countries, governments and international cerebrovascular societies. Europe is the second largest market for neurovascular embolectomy devices. However, the adoption rate of the neurovascular embolectomy devices in Europe is less than that of North America. This is owing to the compliances laid down by the European Union regulatory authority. Pursued by, China and India which also experiences similar stroke risk factors as western countries.
Global neurovascular embolectomy device market is segmented by product and geography. Based on different products, the market is segmented into aspiration devices, stent retrievers. Based on geography, the market is further classified into North America, Europe, China, Japan, Southeast Asia, India, Rest of World.
*Stent Retrievers Held Largest Share In Neurovascular Embolectomy Device Market *
Among neurovascular embolectomy devices, stent retrievers held the principle share as far as income and utilization in 2017. Unique overlapping stent retriever-based technology restores blood flow and retrieves clots from occluded blood vessels in the brain for patients experiencing acute ischemic stroke (AIS) due to a large vessel occlusion (LVO). In fact, the Solitaire device is indicated to reduce stroke-related disability by showing nearly 70% relative improvements in functional outcomes at 90 days in patients suffering a large vessel occlusion. Therefore, holding the prime piece of the overall industry and is foreseen to keep up its predominance over the coming years.
*Key Players*
The market is very focused with numerous worldwide players working in similar geologies, with modest product differentiation. Additionally the worldwide players need to contend with local players who offer comparable items at less expensive rates. The nearby players additionally approach a solid circulation channel which causes them contend with worldwide players. Some of the key players operating in the global neurovascular embolectomy device market profiled in the report include Medtronic, Boston Scientific Corporation, Teleflex Inc, DePuy Synthes, Cook Medical, Straub Medical AG, LeMaitre Vascular, Inc, Edwards Lifesciences Corporation, iVascular SLU among others.
*Inquiry Before Buying - https://www.acumenresearchandconsulting.com/inquiry-before-buying/917*
*Chapter 1. Summary*
*Chapter 2. Industry Overview of Neurovascular Embolectomy Device*
2.1 Definition and Specifications of Neurovascular Embolectomy Device
2.1.1 Definition of Neurovascular Embolectomy Device
2.1.2 Specifications of Neurovascular Embolectomy Device
2.2 Neurovascular Embolectomy Device Segment by Types
2.2.1 Global Neurovascular Embolectomy Device Consumption (Units) and Growth Rate Comparison by Types (2013-2025)
2.2.2 Global Neurovascular Embolectomy Device Consumption Market Share by Types in 2017
2.3 Global Neurovascular Embolectomy Device Market by Regions
2.3.1 Global Neurovascular Embolectomy Device Market Size and Growth Rate Comparison by Regions (2013-2025)
2.3.2 Global Neurovascular Embolectomy Device Revenue Market Share by Applications in 2017
2.3.3 North America Neurovascular Embolectomy Device Status and Prospect (2013-2025)
2.3.4 Europe Neurovascular Embolectomy Device Status and Prospect (2013-2025)
2.3.5 China Neurovascular Embolectomy Device Status and Prospect (2013-2025)
2.3.6 Japan Neurovascular Embolectomy Device Status and Prospect (2013-2025)
2.3.7 India Neurovascular Embolectomy Device Status and Prospect (2013-2025)
2.3.8 Southeast Asia Neurovascular Embolectomy Device Status and Prospect (2013-2025)
2.4 Global Neurovascular Embolectomy Device Market Size
2.4.1 Global Neurovascular Embolectomy Device Revenue Status and Outlook (2013-2025)
2.4.2 Global Neurovascular Embolectomy Device Consumption Status and Outlook (2013-2025)
*Chapter 3. Manufacturing Cost Structure Analysis of Neurovascular Embolectomy Device*
3.1 Raw Material and Suppliers
3.2 Manufacturing Cost Structure Analysis of Neurovascular Embolectomy Device
3.3 Industry Chain Structure of Neurovascular Embolectomy Device
*Chapter 4. Technical Data and Manufacturing Plants Analysis of Neurovascular Embolectomy Device*
4.1 Capacity and Commercial Production Date of Global Neurovascular Embolectomy Device Major Manufacturers in 2017
4.2 Manufacturing Plants Distribution of Global Neurovascular Embolectomy Device Major Manufacturers in 2017
4.3 R&D Status and Technology Source of Global Neurovascular Embolectomy Device Major Manufacturers in 2017
4.4 Raw Materials Sources Analysis of Global Neurovascular Embolectomy Device Major Manufacturers in 2017
*Chapter 5. Global Neurovascular Embolectomy Device Overall Market*
5.1 2013-2018E Overall Market Analysis
5.2 Capacity Analysis
5.2.1 2013-2018E Global Neurovascular Embolectomy Device Capacity and Growth Rate Analysis
5.2.2 2017 Neurovascular Embolectomy Device Capacity Analysis (Company Segment)
5.3 Sales Analysis
5.3.1 2013-2018E Global Neurovascular Embolectomy Device Sales and Growth Rate Analysis
5.3.2 2017 Neurovascular Embolectomy Device Sales Analysis (Company Segment)
5.4 Sales Price Analysis
5.4.1 2013-2018E Global Neurovascular Embolectomy Device Sales Price
5.4.2 2017 Neurovascular Embolectomy Device Sales Price Analysis (Company Segment)
*Chapter 6. Neurovascular Embolectomy Device Regional Market Analysis*
6.1 North America Neurovascular Embolectomy Device Market Analysis
6.1.1 North America Neurovascular Embolectomy Device Market Overview
6.1.2 North America 2013-2018E Neurovascular Embolectomy Device Local Supply, Import, Export, Local Consumption Analysis
6.1.3 North America 2013-2018E Neurovascular Embolectomy Device Sales Price Analysis
6.1.4 North America 2017 Neurovascular Embolectomy Device Market Share Analysis
6.2 Europe Neurovascular Embolectomy Device Market Analysis
6.2.1 Europe Neurovascular Embolectomy Device Market Overview
6.2.2 Europe 2013-2018E Neurovascular Embolectomy Device Local Supply, Import, Export, Local Consumption Analysis
6.2.3 Europe 2013-2018E Neurovascular Embolectomy Device Sales Price Analysis
6.2.4 Europe 2017 Neurovascular Embolectomy Device Market Share Analysis
6.3 China Neurovascular Embolectomy Device Market Analysis
6.3.1 China Neurovascular Embolectomy Device Market Overview
6.3.2 China 2013-2018E Neurovascular Embolectomy Device Local Supply, Import, Export, Local Consumption Analysis
6.3.3 China 2013-2018E Neurovascular Embolectomy Device Sales Price Analysis
6.3.4 China 2017 Neurovascular Embolectomy Device Market Share Analysis
6.4 Southeast Asia Neurovascular Embolectomy Device Market Analysis
6.4.1 Southeast Asia Neurovascular Embolectomy Device Market Overview
6.4.2 Southeast Asia 2013-2018E Neurovascular Embolectomy Device Local Supply, Import, Export, Local Consumption Analysis
6.4.3 Southeast Asia 2013-2018E Neurovascular Embolectomy Device Sales Price Analysis
6.4.4 Southeast Asia 2017 Neurovascular Embolectomy Device Market Share Analysis
6.5 Japan Neurovascular Embolectomy Device Market Analysis
6.5.1 Japan Neurovascular Embolectomy Device Market Overview
6.5.2 Japan 2013-2018E Neurovascular Embolectomy Device Local Supply, Import, Export, Local Consumption Analysis
6.5.3 Japan 2013-2018E Neurovascular Embolectomy Device Sales Price Analysis
6.5.4 Japan 2017 Neurovascular Embolectomy Device Market Share Analysis
6.6 India Neurovascular Embolectomy Device Market Analysis
6.6.1 India Neurovascular Embolectomy Device Market Overview
6.6.2 India 2013-2018E Neurovascular Embolectomy Device Local Supply, Import, Export, Local Consumption Analysis
6.6.3 India 2013-2018E Neurovascular Embolectomy Device Sales Price Analysis
6.6.4 India 2017 Neurovascular Embolectomy Device Market Share Analysis
*Chapter 7. Global 2013-2018E Neurovascular Embolectomy Device Segment Market Analysis (by Type)*
7.1 Global 2013-2018E Neurovascular Embolectomy Device Sales by Type
7.2 Different Types Neurovascular Embolectomy Device Product Interview Price Analysis
7.3 Different Types Neurovascular Embolectomy Device Product Driving Factors Analysis
*Chapter 8. Major Manufacturers Analysis of Neurovascular Embolectomy Device*
8.1 Medtronic
8.1.1 Company Profile
8.1.2 Product Picture and Specifications
8.1.3 Medtronic 2017 Neurovascular Embolectomy Device Sales, Ex-factory Price, Revenue, Gross Margin Analysis
8.1.4 Medtronic 2017 Business Region Distribution Analysis
8.2 Penumbra
8.2.1 Company Profile
8.2.2 Product Picture and Specifications
8.2.3 Penumbra 2017 Neurovascular Embolectomy Device Sales, Ex-factory Price, Revenue, Gross Margin Analysis
8.2.4 Penumbra 2017 Business Region Distribution Analysis
8.3 Biomerics
8.3.1 Company Profile
8.3.2 Product Picture and Specifications
8.3.3 Biomerics 2017 Neurovascular Embolectomy Device Sales, Ex-factory Price, Revenue, Gross Margin Analysis
8.3.4 Biomerics 2017 Business Region Distribution Analysis
8.4 Stryker
8.4.1 Company Profile
8.4.2 Product Picture and Specifications
8.4.3 Stryker 2017 Neurovascular Embolectomy Device Sales, Ex-factory Price, Revenue, Gross Margin Analysis
8.4.4 Stryker 2017 Business Region Distribution Analysis
8.5 Neuravi
8.5.1 Company Profile
8.5.2 Product Picture and Specifications
8.5.3 Neuravi 2017 Neurovascular Embolectomy Device Sales, Ex-factory Price, Revenue, Gross Margin Analysis
8.5.4 Neuravi 2017 Business Region Distribution Analysis
8.6 phenox GmbH
8.6.1 Company Profile
8.6.2 Product Picture and Specifications
8.6.3 phenox GmbH 2017 Neurovascular Embolectomy Device Sales, Ex-factory Price, Revenue, Gross Margin Analysis
8.6.4 phenox GmbH 2017 Business Region Distribution Analysis
8.7 Rapid Medical
8.7.1 Company Profile
8.7.2 Product Picture and Specifications
8.7.3 Rapid Medical 2017 Neurovascular Embolectomy Device Sales, Ex-factory Price, Revenue, Gross Margin Analysis
8.7.4 Rapid Medical 2017 Business Region Distribution Analysis
8.8 Cardiva
8.8.1 Company Profile
8.8.2 Product Picture and Specifications
8.8.3 Cardiva 2017 Neurovascular Embolectomy Device Sales, Ex-factory Price, Revenue, Gross Margin Analysis
8.8.4 Cardiva 2017 Business Region Distribution Analysis
*Chapter 9. Development Trend of Analysis of Neurovascular Embolectomy Device Market*
9.1 Global Neurovascular Embolectomy Device Market Trend Analysis
9.1.1 Global 2018-2025 Neurovascular Embolectomy Device Market Size (Volume and Value) Forecast
9.1.2 Global Neurovascular Embolectomy Device Revenue and Growth Forecast (2018-2025)
9.1.3 Global 2018-2025 Neurovascular Embolectomy Device Sales Price Forecast
9.2 Neurovascular Embolectomy Device Regional Market Trend
9.2.1 North America 2018-2025 Neurovascular Embolectomy Device Consumption Forecast
9.2.2 Europe 2018-2025 Neurovascular Embolectomy Device Consumption Forecast
9.2.3 China 2018-2025 Neurovascular Embolectomy Device Consumption Forecast
9.2.4 Southeast Asia 2018-2025 Neurovascular Embolectomy Device Consumption Forecast
9.2.5 Japan 2018-2025 Neurovascular Embolectomy Device Consumption Forecast
9.2.6 India 2018-2025 Neurovascular Embolectomy Device Consumption Forecast
9.3 Neurovascular Embolectomy Device Market Trend (Product Type)
*Chapter 10. Neurovascular Embolectomy Device Marketing Type Analysis*
10.1 Neurovascular Embolectomy Device Regional Marketing Type Analysis
10.1.1 Direct Marketing
10.1.2 Indirect Marketing
10.1.3 Marketing Channel Development Trend
10.2 Neurovascular Embolectomy Device International Trade Type Analysis
10.3 Traders or Distributors with Contact Information of Neurovascular Embolectomy Device by Regions
10.4 Neurovascular Embolectomy Device Supply Chain Analysis
*Chapter 11. Consumers Analysis of Neurovascular Embolectomy Device*
11.1 Consumer Analysis
*Chapter 12. Conclusion of the Global Neurovascular Embolectomy Device Market Professional Survey Report 2016*
*Chapter 13. Methodology and Data Source*
13.1 Methodology/Research Approach
13.1.1 Research Programs/Design
13.1.2 Market Size Estimation
13.1.3 Market Breakdown and Data Triangulation
13.2 Data Source
13.2.1 Secondary Sources
13.2.2 Primary Sources
*The report is readily available and can be dispatched immediately after payment confirmation.*
*Buy this premium research report - https://www.acumenresearchandconsulting.com/buy-now/0/917 *
*Would like to place an order or any question, please feel free to contact at sales@acumenresearchandconsulting.com | +1 407 915 4157 *
*Follow Us:*
*https://twitter.com/AcumenRC*
*https://www.facebook.com/acumenresearchandconsulting*
*https://www.linkedin.com/company/acumen-research-and-consulting/*
*Browse More Press Releases: http://trendsdesk.com/* Reported by GlobeNewswire 2 hours ago.
LOS ANGELES, Dec. 12, 2018 (GLOBE NEWSWIRE) -- *Global neurovascular embolectomy device market* is expected to reach the market value of around $1.9 billion by 2025 and is projected to grow at a CAGR of over 17% in terms of revenue during the period 2018 – 2025. Escalating cases of stroke with changing lifestyle and environmental calamities have boosted the demand for neurovascular embolectomy devices. Neurovascular embolectomy device market is driven by increasing cases of strokes, innovation and product development, international trade, and increasing consumer awareness for strokes across the globe. Superior healthcare treatment with better devices that offer improved success rates increases the adoption of neurovascular embolectomy devices. Growing consumer knowledge for post surgery safety has increased the application of apt devices suitable for patients. Hence, rising expenditure capacity and increasing knowledge of consumers are also fueling the demand for neurovascular embolectomy devices. The strengthening economic conditions in different countries, as well suggest decent growth break-through for the stake-holders of neurovascular embolectomy device market.
*Download Report Sample Pages@ https://www.acumenresearchandconsulting.com/request-sample/917 *
The standardization of legal framework by global and regional healthcare organizations and government has generated opportunities for manufacturers to invest in product and market development. Focusing on research & development by government and industry players can take the neurovascular embolectomy device market to sustainable market growth. Moreover, this has paved a way for increased international trade thereby promoting healthy sharing of technology, education, neurological science and quality improvement.
Federal & regulatory body laws and regulations possess to be the prime challenge to the neurovascular embolectomy device market. According to key industrialists and opinion leaders, the norms and procedures for neurovascular embolectomy device research & development and industrial applications have been strictly regulated due to safety concerns. This may affect the demand for both the neurovascular embolectomy device industry and its end-use application. In addition, global downturn and high cost of technology also possesses a potential risk to the growth of the neurovascular embolectomy device market.
*View Detailed Information@ https://www.acumenresearchandconsulting.com/neurovascular-cmbolectomy-device-market *
*Bare Platinum Coils to Aid Growth of Market*
Neurovascular device market has experienced an intense move regarding products and systems. Specialists need to receive instruments and procedures that offer higher window for stroke treatment with high achievement rate and negligible post-surgical effect. This is sustained by the way that interest for uncovered platinum loops is developing at a higher pace in contrast with coated coils. This is mainly because of huge expenses related to coated coils and their less enhanced clinical results contrasted with bare platinum coils. Also, stroke treatment includes high healthcare spending that drives the focus on improvement of efficient treatment strategies.
*Regional Analysis *
Currently, North America is the largest market for neurovascular devices. As per Stroke Association, approximately 1 million Americans each year are affected by stokes. Also, this is one of the leading triggers of disability and death. In the U.S., the financial drain of stroke is valued at around USD 30 billion annually, which includes the expenditure on health care services, prescriptions, and reduced output. The ASA has put up great effort to transform the existing healthcare systems and patients worldwide by collaborating with other countries, governments and international cerebrovascular societies. Europe is the second largest market for neurovascular embolectomy devices. However, the adoption rate of the neurovascular embolectomy devices in Europe is less than that of North America. This is owing to the compliances laid down by the European Union regulatory authority. Pursued by, China and India which also experiences similar stroke risk factors as western countries.
Global neurovascular embolectomy device market is segmented by product and geography. Based on different products, the market is segmented into aspiration devices, stent retrievers. Based on geography, the market is further classified into North America, Europe, China, Japan, Southeast Asia, India, Rest of World.
*Stent Retrievers Held Largest Share In Neurovascular Embolectomy Device Market *
Among neurovascular embolectomy devices, stent retrievers held the principle share as far as income and utilization in 2017. Unique overlapping stent retriever-based technology restores blood flow and retrieves clots from occluded blood vessels in the brain for patients experiencing acute ischemic stroke (AIS) due to a large vessel occlusion (LVO). In fact, the Solitaire device is indicated to reduce stroke-related disability by showing nearly 70% relative improvements in functional outcomes at 90 days in patients suffering a large vessel occlusion. Therefore, holding the prime piece of the overall industry and is foreseen to keep up its predominance over the coming years.
*Key Players*
The market is very focused with numerous worldwide players working in similar geologies, with modest product differentiation. Additionally the worldwide players need to contend with local players who offer comparable items at less expensive rates. The nearby players additionally approach a solid circulation channel which causes them contend with worldwide players. Some of the key players operating in the global neurovascular embolectomy device market profiled in the report include Medtronic, Boston Scientific Corporation, Teleflex Inc, DePuy Synthes, Cook Medical, Straub Medical AG, LeMaitre Vascular, Inc, Edwards Lifesciences Corporation, iVascular SLU among others.
*Inquiry Before Buying - https://www.acumenresearchandconsulting.com/inquiry-before-buying/917*
*Chapter 1. Summary*
*Chapter 2. Industry Overview of Neurovascular Embolectomy Device*
2.1 Definition and Specifications of Neurovascular Embolectomy Device
2.1.1 Definition of Neurovascular Embolectomy Device
2.1.2 Specifications of Neurovascular Embolectomy Device
2.2 Neurovascular Embolectomy Device Segment by Types
2.2.1 Global Neurovascular Embolectomy Device Consumption (Units) and Growth Rate Comparison by Types (2013-2025)
2.2.2 Global Neurovascular Embolectomy Device Consumption Market Share by Types in 2017
2.3 Global Neurovascular Embolectomy Device Market by Regions
2.3.1 Global Neurovascular Embolectomy Device Market Size and Growth Rate Comparison by Regions (2013-2025)
2.3.2 Global Neurovascular Embolectomy Device Revenue Market Share by Applications in 2017
2.3.3 North America Neurovascular Embolectomy Device Status and Prospect (2013-2025)
2.3.4 Europe Neurovascular Embolectomy Device Status and Prospect (2013-2025)
2.3.5 China Neurovascular Embolectomy Device Status and Prospect (2013-2025)
2.3.6 Japan Neurovascular Embolectomy Device Status and Prospect (2013-2025)
2.3.7 India Neurovascular Embolectomy Device Status and Prospect (2013-2025)
2.3.8 Southeast Asia Neurovascular Embolectomy Device Status and Prospect (2013-2025)
2.4 Global Neurovascular Embolectomy Device Market Size
2.4.1 Global Neurovascular Embolectomy Device Revenue Status and Outlook (2013-2025)
2.4.2 Global Neurovascular Embolectomy Device Consumption Status and Outlook (2013-2025)
*Chapter 3. Manufacturing Cost Structure Analysis of Neurovascular Embolectomy Device*
3.1 Raw Material and Suppliers
3.2 Manufacturing Cost Structure Analysis of Neurovascular Embolectomy Device
3.3 Industry Chain Structure of Neurovascular Embolectomy Device
*Chapter 4. Technical Data and Manufacturing Plants Analysis of Neurovascular Embolectomy Device*
4.1 Capacity and Commercial Production Date of Global Neurovascular Embolectomy Device Major Manufacturers in 2017
4.2 Manufacturing Plants Distribution of Global Neurovascular Embolectomy Device Major Manufacturers in 2017
4.3 R&D Status and Technology Source of Global Neurovascular Embolectomy Device Major Manufacturers in 2017
4.4 Raw Materials Sources Analysis of Global Neurovascular Embolectomy Device Major Manufacturers in 2017
*Chapter 5. Global Neurovascular Embolectomy Device Overall Market*
5.1 2013-2018E Overall Market Analysis
5.2 Capacity Analysis
5.2.1 2013-2018E Global Neurovascular Embolectomy Device Capacity and Growth Rate Analysis
5.2.2 2017 Neurovascular Embolectomy Device Capacity Analysis (Company Segment)
5.3 Sales Analysis
5.3.1 2013-2018E Global Neurovascular Embolectomy Device Sales and Growth Rate Analysis
5.3.2 2017 Neurovascular Embolectomy Device Sales Analysis (Company Segment)
5.4 Sales Price Analysis
5.4.1 2013-2018E Global Neurovascular Embolectomy Device Sales Price
5.4.2 2017 Neurovascular Embolectomy Device Sales Price Analysis (Company Segment)
*Chapter 6. Neurovascular Embolectomy Device Regional Market Analysis*
6.1 North America Neurovascular Embolectomy Device Market Analysis
6.1.1 North America Neurovascular Embolectomy Device Market Overview
6.1.2 North America 2013-2018E Neurovascular Embolectomy Device Local Supply, Import, Export, Local Consumption Analysis
6.1.3 North America 2013-2018E Neurovascular Embolectomy Device Sales Price Analysis
6.1.4 North America 2017 Neurovascular Embolectomy Device Market Share Analysis
6.2 Europe Neurovascular Embolectomy Device Market Analysis
6.2.1 Europe Neurovascular Embolectomy Device Market Overview
6.2.2 Europe 2013-2018E Neurovascular Embolectomy Device Local Supply, Import, Export, Local Consumption Analysis
6.2.3 Europe 2013-2018E Neurovascular Embolectomy Device Sales Price Analysis
6.2.4 Europe 2017 Neurovascular Embolectomy Device Market Share Analysis
6.3 China Neurovascular Embolectomy Device Market Analysis
6.3.1 China Neurovascular Embolectomy Device Market Overview
6.3.2 China 2013-2018E Neurovascular Embolectomy Device Local Supply, Import, Export, Local Consumption Analysis
6.3.3 China 2013-2018E Neurovascular Embolectomy Device Sales Price Analysis
6.3.4 China 2017 Neurovascular Embolectomy Device Market Share Analysis
6.4 Southeast Asia Neurovascular Embolectomy Device Market Analysis
6.4.1 Southeast Asia Neurovascular Embolectomy Device Market Overview
6.4.2 Southeast Asia 2013-2018E Neurovascular Embolectomy Device Local Supply, Import, Export, Local Consumption Analysis
6.4.3 Southeast Asia 2013-2018E Neurovascular Embolectomy Device Sales Price Analysis
6.4.4 Southeast Asia 2017 Neurovascular Embolectomy Device Market Share Analysis
6.5 Japan Neurovascular Embolectomy Device Market Analysis
6.5.1 Japan Neurovascular Embolectomy Device Market Overview
6.5.2 Japan 2013-2018E Neurovascular Embolectomy Device Local Supply, Import, Export, Local Consumption Analysis
6.5.3 Japan 2013-2018E Neurovascular Embolectomy Device Sales Price Analysis
6.5.4 Japan 2017 Neurovascular Embolectomy Device Market Share Analysis
6.6 India Neurovascular Embolectomy Device Market Analysis
6.6.1 India Neurovascular Embolectomy Device Market Overview
6.6.2 India 2013-2018E Neurovascular Embolectomy Device Local Supply, Import, Export, Local Consumption Analysis
6.6.3 India 2013-2018E Neurovascular Embolectomy Device Sales Price Analysis
6.6.4 India 2017 Neurovascular Embolectomy Device Market Share Analysis
*Chapter 7. Global 2013-2018E Neurovascular Embolectomy Device Segment Market Analysis (by Type)*
7.1 Global 2013-2018E Neurovascular Embolectomy Device Sales by Type
7.2 Different Types Neurovascular Embolectomy Device Product Interview Price Analysis
7.3 Different Types Neurovascular Embolectomy Device Product Driving Factors Analysis
*Chapter 8. Major Manufacturers Analysis of Neurovascular Embolectomy Device*
8.1 Medtronic
8.1.1 Company Profile
8.1.2 Product Picture and Specifications
8.1.3 Medtronic 2017 Neurovascular Embolectomy Device Sales, Ex-factory Price, Revenue, Gross Margin Analysis
8.1.4 Medtronic 2017 Business Region Distribution Analysis
8.2 Penumbra
8.2.1 Company Profile
8.2.2 Product Picture and Specifications
8.2.3 Penumbra 2017 Neurovascular Embolectomy Device Sales, Ex-factory Price, Revenue, Gross Margin Analysis
8.2.4 Penumbra 2017 Business Region Distribution Analysis
8.3 Biomerics
8.3.1 Company Profile
8.3.2 Product Picture and Specifications
8.3.3 Biomerics 2017 Neurovascular Embolectomy Device Sales, Ex-factory Price, Revenue, Gross Margin Analysis
8.3.4 Biomerics 2017 Business Region Distribution Analysis
8.4 Stryker
8.4.1 Company Profile
8.4.2 Product Picture and Specifications
8.4.3 Stryker 2017 Neurovascular Embolectomy Device Sales, Ex-factory Price, Revenue, Gross Margin Analysis
8.4.4 Stryker 2017 Business Region Distribution Analysis
8.5 Neuravi
8.5.1 Company Profile
8.5.2 Product Picture and Specifications
8.5.3 Neuravi 2017 Neurovascular Embolectomy Device Sales, Ex-factory Price, Revenue, Gross Margin Analysis
8.5.4 Neuravi 2017 Business Region Distribution Analysis
8.6 phenox GmbH
8.6.1 Company Profile
8.6.2 Product Picture and Specifications
8.6.3 phenox GmbH 2017 Neurovascular Embolectomy Device Sales, Ex-factory Price, Revenue, Gross Margin Analysis
8.6.4 phenox GmbH 2017 Business Region Distribution Analysis
8.7 Rapid Medical
8.7.1 Company Profile
8.7.2 Product Picture and Specifications
8.7.3 Rapid Medical 2017 Neurovascular Embolectomy Device Sales, Ex-factory Price, Revenue, Gross Margin Analysis
8.7.4 Rapid Medical 2017 Business Region Distribution Analysis
8.8 Cardiva
8.8.1 Company Profile
8.8.2 Product Picture and Specifications
8.8.3 Cardiva 2017 Neurovascular Embolectomy Device Sales, Ex-factory Price, Revenue, Gross Margin Analysis
8.8.4 Cardiva 2017 Business Region Distribution Analysis
*Chapter 9. Development Trend of Analysis of Neurovascular Embolectomy Device Market*
9.1 Global Neurovascular Embolectomy Device Market Trend Analysis
9.1.1 Global 2018-2025 Neurovascular Embolectomy Device Market Size (Volume and Value) Forecast
9.1.2 Global Neurovascular Embolectomy Device Revenue and Growth Forecast (2018-2025)
9.1.3 Global 2018-2025 Neurovascular Embolectomy Device Sales Price Forecast
9.2 Neurovascular Embolectomy Device Regional Market Trend
9.2.1 North America 2018-2025 Neurovascular Embolectomy Device Consumption Forecast
9.2.2 Europe 2018-2025 Neurovascular Embolectomy Device Consumption Forecast
9.2.3 China 2018-2025 Neurovascular Embolectomy Device Consumption Forecast
9.2.4 Southeast Asia 2018-2025 Neurovascular Embolectomy Device Consumption Forecast
9.2.5 Japan 2018-2025 Neurovascular Embolectomy Device Consumption Forecast
9.2.6 India 2018-2025 Neurovascular Embolectomy Device Consumption Forecast
9.3 Neurovascular Embolectomy Device Market Trend (Product Type)
*Chapter 10. Neurovascular Embolectomy Device Marketing Type Analysis*
10.1 Neurovascular Embolectomy Device Regional Marketing Type Analysis
10.1.1 Direct Marketing
10.1.2 Indirect Marketing
10.1.3 Marketing Channel Development Trend
10.2 Neurovascular Embolectomy Device International Trade Type Analysis
10.3 Traders or Distributors with Contact Information of Neurovascular Embolectomy Device by Regions
10.4 Neurovascular Embolectomy Device Supply Chain Analysis
*Chapter 11. Consumers Analysis of Neurovascular Embolectomy Device*
11.1 Consumer Analysis
*Chapter 12. Conclusion of the Global Neurovascular Embolectomy Device Market Professional Survey Report 2016*
*Chapter 13. Methodology and Data Source*
13.1 Methodology/Research Approach
13.1.1 Research Programs/Design
13.1.2 Market Size Estimation
13.1.3 Market Breakdown and Data Triangulation
13.2 Data Source
13.2.1 Secondary Sources
13.2.2 Primary Sources
*The report is readily available and can be dispatched immediately after payment confirmation.*
*Buy this premium research report - https://www.acumenresearchandconsulting.com/buy-now/0/917 *
*Would like to place an order or any question, please feel free to contact at sales@acumenresearchandconsulting.com | +1 407 915 4157 *
*Follow Us:*
*https://twitter.com/AcumenRC*
*https://www.facebook.com/acumenresearchandconsulting*
*https://www.linkedin.com/company/acumen-research-and-consulting/*
*Browse More Press Releases: http://trendsdesk.com/* Reported by GlobeNewswire 2 hours ago.
↧
DAX Extends Recent Gains, Adds Over 1%
The German market is up sharply, mirroring the overall bullish mood across Asia and Europe, amid rising optimism about the U.S. and China reaching a trade deal.
Reported by RTTNews 2 hours ago.
↧
↧
5 detained as France hunts Christmas market terror suspect
STRASBOURG, France -- French authorities detained five people as they hunted Wednesday for a suspected extremist who sprayed gunfire at one of Europe's most famous Christmas markets in the eastern city of Strasbourg, killing three and wounding at least 13 and putting the whole country on edge anew.
Reported by Newsday 1 hour ago.
↧
Global Chocolate & Confectionery Processing Equipment Market 2018-2024: Growing Focus on Safety of Confectionery Products and the Safety of Workers
Dublin, Dec. 12, 2018 (GLOBE NEWSWIRE) -- The "Chocolate & Confectionery Processing Equipment Market By Type (Depositors, Formers, Coating & Spraying Systems, Mixer, & Cooler), By Application (Soft Confectionery, Hard Candies, Chewing Gums, Gummies/Jellies), & Geography - Global Forecast to 2024" report has been added to *ResearchAndMarkets.com's* offering.The global chocolate and confectionery processing equipment market is expected to grow at a CAGR of 8.0% from 2018 to reach $6,971.8 million by 2024
Factors such as the increasing consumer demand for confectionery items, growth in retail industry, technological advancements, and a growing focus on food safety of confectionery products and safety of workers are driving the growth of the global chocolate and confectionery processing equipment market. However, the high cost of equipment hinders the growth of this market to some extent. In addition, the lack of a trained labour force in many parts of the globe poses a great challenge to the global chocolate processing equipment manufacturers.
Depositors dominated the global chocolate and confectionery processing equipment market in 2017, mainly due to significant development in the depositing technology to meet increasing market demand for high-quality and innovative products and increased demand for confectionery products from developing markets.
Soft confectionery segment dominated the chocolate and confectionery processing equipment market, as it is one of the most consumed confectionery products by almost all age groups in all regions as well as it is a key ingredient in many food products; increase in awareness regarding the health benefits of chocolate; and inclination of consumers toward functional dark and sugar-free chocolates.
The largest share of this region is mainly attributed to increasing demand of functional and premium chocolate and confectionery products in emerging and developing countries including India, China, Indonesia, and Thailand; higher population base; and increasing expenditure on convenience and ready-to-eat products.*Key Topics Covered:**1. Introduction*
1.1. Market Ecosystem
1.2. Currency and Limitations
1.3. Key Stakeholders
*2. Research Methodology*
2.1. Research Process
2.1.1. Secondary Research
2.1.2. Primary Research
2.1.3. Market Size Estimation
*3. Executive Summary*
3.1. Introduction
3.2. Market Dynamics
3.3. Segment Analysis
3.3.1. Type Analysis
3.3.2. Application Analysis
3.4. Regional Analysis
3.5. Key Players
*4. Market Insights*
4.1. Introduction
4.2. Drivers
4.2.1. Increasing Consumer Demand for Confectionary Items
4.2.2. Growth of the Global Retail Industry
4.2.3. Technological Advancements
4.2.4. Growing Focus on Safety of Confectionery Products and the Safety of Workers
4.3. Restraints
4.3.1. High Cost of Equipment Due to its High Production Cost
4.4. Opportunities
4.4.1. Emerging Economies- Asia-Pacific, Latin America, and Middle East and Africa
4.5. Challenges
4.5.1. Lack of Skilled Labour Force
*5. Global Chocolate and Confectionery Processing Equipment Market, by Type*
5.1. Introduction
5.1.1. Depositors
5.1.2. Formers
5.1.3. Coating and Spraying Systems
5.1.4. Mixers
5.1.5. Coolers
5.1.6. Others
*6. Global Chocolate Processing Equipment Market, by Application*
6.1. Introduction
6.2. Soft Confectionery
6.3. Hard Candies
6.4. Chewing Gums
6.5. Gummies & Jellies
6.6. Other
*7. Chocolate Processing Equipment Market, by Geography*
7.1. Introduction
7.2. North America
7.2.1. Introduction
7.2.2. U.S.
7.2.3. Canada
7.3. Europe
7.3.1. Germany
7.3.2. France
7.3.3. Italy
7.3.4. U.K.
7.3.5. Spain
7.3.6. The Netherlands
7.3.7. Rest of Europe
7.4. Asia-Pacific
7.4.1. China
7.4.2. India
7.4.3. Japan
7.4.4. Australia
7.4.5. Rest of Asia-Pacific
7.5. Rest of World
7.5.1. Latin America
7.5.1.1. Brazil
7.5.1.2. Mexico
7.5.1.3. Argentina
7.5.1.4. Rest of Latin America
7.5.2. Middle East and Africa
*8. Company Profiles (Business Overview, Financial Overview, Product Portfolio, and Recent Developments)*
8.1. Buhler AG
8.2. GEA Group Aktiengesellschaft
8.3. John Bean Technologies Corporation
8.4. Heat and Control Inc.
8.5. Alfa Laval Ab
8.6. Robert Bosch Packaging Technology GmbH
8.7. Aasted APS
8.8. Baker Perkins Limited
8.9. Tomric Systems, Inc
8.10. Caotech B.V.
8.11. Sollich KG
8.12. Apex Machinery & Equipment Co., Ltd.
8.13. Royal Duyvis Wiener B.V.
8.14. Tecno 3 S.R.L.
8.15. BCH LimitedFor more information about this report visit https://www.researchandmarkets.com/research/k42wrk/global_chocolate?w=12
Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.
CONTACT:
CONTACT: ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics: Snacks and Confectionery, Chocolate and Cocoa Products, Industrial Machinery Reported by GlobeNewswire 1 hour ago.
Factors such as the increasing consumer demand for confectionery items, growth in retail industry, technological advancements, and a growing focus on food safety of confectionery products and safety of workers are driving the growth of the global chocolate and confectionery processing equipment market. However, the high cost of equipment hinders the growth of this market to some extent. In addition, the lack of a trained labour force in many parts of the globe poses a great challenge to the global chocolate processing equipment manufacturers.
Depositors dominated the global chocolate and confectionery processing equipment market in 2017, mainly due to significant development in the depositing technology to meet increasing market demand for high-quality and innovative products and increased demand for confectionery products from developing markets.
Soft confectionery segment dominated the chocolate and confectionery processing equipment market, as it is one of the most consumed confectionery products by almost all age groups in all regions as well as it is a key ingredient in many food products; increase in awareness regarding the health benefits of chocolate; and inclination of consumers toward functional dark and sugar-free chocolates.
The largest share of this region is mainly attributed to increasing demand of functional and premium chocolate and confectionery products in emerging and developing countries including India, China, Indonesia, and Thailand; higher population base; and increasing expenditure on convenience and ready-to-eat products.*Key Topics Covered:**1. Introduction*
1.1. Market Ecosystem
1.2. Currency and Limitations
1.3. Key Stakeholders
*2. Research Methodology*
2.1. Research Process
2.1.1. Secondary Research
2.1.2. Primary Research
2.1.3. Market Size Estimation
*3. Executive Summary*
3.1. Introduction
3.2. Market Dynamics
3.3. Segment Analysis
3.3.1. Type Analysis
3.3.2. Application Analysis
3.4. Regional Analysis
3.5. Key Players
*4. Market Insights*
4.1. Introduction
4.2. Drivers
4.2.1. Increasing Consumer Demand for Confectionary Items
4.2.2. Growth of the Global Retail Industry
4.2.3. Technological Advancements
4.2.4. Growing Focus on Safety of Confectionery Products and the Safety of Workers
4.3. Restraints
4.3.1. High Cost of Equipment Due to its High Production Cost
4.4. Opportunities
4.4.1. Emerging Economies- Asia-Pacific, Latin America, and Middle East and Africa
4.5. Challenges
4.5.1. Lack of Skilled Labour Force
*5. Global Chocolate and Confectionery Processing Equipment Market, by Type*
5.1. Introduction
5.1.1. Depositors
5.1.2. Formers
5.1.3. Coating and Spraying Systems
5.1.4. Mixers
5.1.5. Coolers
5.1.6. Others
*6. Global Chocolate Processing Equipment Market, by Application*
6.1. Introduction
6.2. Soft Confectionery
6.3. Hard Candies
6.4. Chewing Gums
6.5. Gummies & Jellies
6.6. Other
*7. Chocolate Processing Equipment Market, by Geography*
7.1. Introduction
7.2. North America
7.2.1. Introduction
7.2.2. U.S.
7.2.3. Canada
7.3. Europe
7.3.1. Germany
7.3.2. France
7.3.3. Italy
7.3.4. U.K.
7.3.5. Spain
7.3.6. The Netherlands
7.3.7. Rest of Europe
7.4. Asia-Pacific
7.4.1. China
7.4.2. India
7.4.3. Japan
7.4.4. Australia
7.4.5. Rest of Asia-Pacific
7.5. Rest of World
7.5.1. Latin America
7.5.1.1. Brazil
7.5.1.2. Mexico
7.5.1.3. Argentina
7.5.1.4. Rest of Latin America
7.5.2. Middle East and Africa
*8. Company Profiles (Business Overview, Financial Overview, Product Portfolio, and Recent Developments)*
8.1. Buhler AG
8.2. GEA Group Aktiengesellschaft
8.3. John Bean Technologies Corporation
8.4. Heat and Control Inc.
8.5. Alfa Laval Ab
8.6. Robert Bosch Packaging Technology GmbH
8.7. Aasted APS
8.8. Baker Perkins Limited
8.9. Tomric Systems, Inc
8.10. Caotech B.V.
8.11. Sollich KG
8.12. Apex Machinery & Equipment Co., Ltd.
8.13. Royal Duyvis Wiener B.V.
8.14. Tecno 3 S.R.L.
8.15. BCH LimitedFor more information about this report visit https://www.researchandmarkets.com/research/k42wrk/global_chocolate?w=12
Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.
CONTACT:
CONTACT: ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics: Snacks and Confectionery, Chocolate and Cocoa Products, Industrial Machinery Reported by GlobeNewswire 1 hour ago.
↧
Global $57.5 Billion Vaccines (Pneumococcal, Influenza, DTP, HPV, Hepatitis, Meningococcal, Rotavirus, Polio, MMR) Market Forecast to 2025
Dublin, Dec. 12, 2018 (GLOBE NEWSWIRE) -- The "Vaccines Market By Indication (Pneumococcal, Influenza, DTP, HPV, Hepatitis, Meningococcal, Rotavirus, Polio, MMR), Type (Live, Toxoid), Route Of Administration (IM, SC, Oral), Valence (Monovalent, Multivalent) & Geography - Global Forecast to 2025" report has been added to *ResearchAndMarkets.com's* offering.The global vaccines market is expected to reach $57.50 billion by 2025 from $33.70 billion in 2018, growing at a CAGR of 7.9%
The growth of this market is mainly attributed to high prevalence of diseases, increasing government initiatives towards immunization, rising adoption of vaccines, technological advancements in vaccine industry, and strong pipeline for vaccines. In addition, increasing epidemic potentials and growing focus on therapeutic vaccines are expected to offer significant growth opportunities for players operating in the vaccines market.However, the high costs associated with vaccine development, stringent regulations and a longer timeline for vaccine development, as well as product recalls, are expected to hinder the growth of this market to a certain extent. On the other hand, the new product development cycle for vaccines and need for more training dedicated to vaccinology pose a major challenge for vaccines industry.
In 2017, pneumococcal disease accounted for the largest share of the vaccines market. The large share of this segment is mainly attributed to high prevalence of pneumococcal disease in pediatric, elderly, and immunocompromised populations. In addition, growing number of pneumococcal diseases associated with chronic disease patients is further driving the adoption of the pneumococcal vaccines.
The route of administration is the lane by which a vaccine is brought into contact with the body. Vaccines are administered through Intramuscular (IM), Subcutaneous (SC/SQ), oral, and others (intradermal and nasal). In 2017, the intramuscular accounted for the largest share of the of the global vaccines market. The large share of this segment is mainly due to availability of wide range of vaccines for IM.
Subunit, recombinant, polysaccharide, and conjugate vaccines accounted for the largest share of the global vaccines market in 2017. The large share of this segment is mainly attributed to increasing focus of companies towards recombinant and conjugate vaccines, growing prevalence of diseases, and increasing government initiatives.
An in-depth analysis of the geographical scenario of the industry provides detailed qualitative and quantitative insights about the five major geographies (North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa) along with the coverage of major countries in each region.
North America accounted for largest share of vaccines market in 2017. The large share of this segment is mainly attributed to the well established vaccination program in the region, increasing prevalence of diseases, growing adoption of advanced vaccines, and large pool of key players.
The Asia-Pacific vaccines market is expected to grow at a highest CAGR of 8.9%. The growth in the APAC market is mainly attributed to large patient pool, rising prevalence of diseases, growing awareness on vaccination, increasing government initiatives, and expanding presence of key players in this region. In addition, factors such as increasing disposable income and growing awareness about heath in emerging countries are further propelling the demand of vaccines in APAC.*Key Topics Covered:**1. Introduction*
1.1. Market Definition
1.2. Market Segmentation
1.3. Currency and Limitations
1.4. Key Stakeholders
*2. Research Methodology*
2.1. Research Process
2.1.1. Secondary Research
2.1.2. Primary Research
2.1.3. Market Size Estimation
*3. Executive Summary*
3.1. Introduction
3.2. Market Dynamics
3.3. Product Segment Analysis
3.4. Regional Market Analysis
3.5. Competitive Analysis
*4. Market Insights*
4.1. Market Overview
4.2. Market Dynamics
4.3. Drivers
4.3.1. Strong Vaccines Pipeline
4.3.2. Rising Adoption of Vaccination
4.3.3. Increasing Government Focus on Immunization Programs
4.3.4. Technological Progress in Vaccine Administration
4.4. Restraints
4.4.1. High Cost Associated with Vaccine Development
4.4.2. Longer Timelines for Vaccine Manufacturing
4.5. Opportunities
4.5.1. Increasing Epidemic Potentials
4.5.2. Growing Focus on Therapeutic Vaccines
4.5.3. Growth Prospects in Emerging Markets
4.5.4. Increasing Use of Adjuvants in Vaccines
4.6. Challenges
4.6.1. Product Recalls
4.6.2. Inadequate Access to Vaccines
*5. Industry Analysis*
5.1. Regulatory Analysis
5.2. Pipeline Analysis
5.3. Unmet Needs Analysis
5.4. Pricing Analysis, by Region
*6. Global Vaccines Market, by Indication*
6.1. Overview
6.2. Pneumococcal Disease
6.3. Influenza
6.4. DTP
6.5. Human Papilloma Virus (HPV)
6.6. Meningococcal Disease
6.7. Poliomyelitis (Polio)
6.8. MMR
6.9. Rotavirus
6.10. Hepatitis
6.11. Others
*7. Global Vaccines Market, by Route of Administration*
7.1. Overview
7.2. Intramuscular (IM)
7.3. Subcutaneous (SC)
7.4. Oral
7.5. Other (Routes of Administration)
*8. Global Vaccines Market, by Type/Antigen*
8.1. Overview
8.2. Subunit & Conjugate Vaccines
8.3. Inactivated Vaccines
8.4. Live Attenuated Vaccines
8.5. Toxoid Vaccines
*9. Global Vaccines Market, by Valence*
9.1. Overview
9.2. Multivalent Vaccines
9.3. Monovalent Vaccines
*10. Vaccines Market, by Region*
10.1. Overview
10.2. North America
10.2.1. U.S.
10.2.2. Canada
10.3. Europe
10.3.1. U.K.
10.3.2. Germany
10.3.3. France
10.3.4. Italy
10.3.5. Spain
10.3.6. Rest of Europe
10.4. Asia Pacific
10.4.1. China
10.4.2. Japan
10.4.3. India
10.4.4. Rest of Asia Pacific
10.5. Latin America
10.6. Middle East & Africa
*11. Competitive Landscape*
11.1. Overview
11.2. Competition Matrix
11.3. Market Share Analysis
11.3.1. Market Share Analysis, by Company
11.3.2. Market Share Analysis, by Product
*12. Company Profiles*
12.1. Sanofi Pasteur
12.2. Merck & Co., Inc.
12.3. GlaxoSmithKline Plc
12.4. Pfizer, Inc.
12.5. Johnson & Johnson
12.6. Daiichi Sankyo
12.7. Takeda Pharmaceutical Co. Ltd.
12.8. CSL Limited
12.9. Emergent BioSolutions Inc.
12.10. AstraZenecaFor more information about this report visit https://www.researchandmarkets.com/research/wk2zpk/global_57_5?w=12
Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.
CONTACT:
CONTACT: ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics: Gastrointestinal Drugs , Vaccines, Cancer Vaccines, Liver and Kidney Disorders Drugs Reported by GlobeNewswire 1 hour ago.
The growth of this market is mainly attributed to high prevalence of diseases, increasing government initiatives towards immunization, rising adoption of vaccines, technological advancements in vaccine industry, and strong pipeline for vaccines. In addition, increasing epidemic potentials and growing focus on therapeutic vaccines are expected to offer significant growth opportunities for players operating in the vaccines market.However, the high costs associated with vaccine development, stringent regulations and a longer timeline for vaccine development, as well as product recalls, are expected to hinder the growth of this market to a certain extent. On the other hand, the new product development cycle for vaccines and need for more training dedicated to vaccinology pose a major challenge for vaccines industry.
In 2017, pneumococcal disease accounted for the largest share of the vaccines market. The large share of this segment is mainly attributed to high prevalence of pneumococcal disease in pediatric, elderly, and immunocompromised populations. In addition, growing number of pneumococcal diseases associated with chronic disease patients is further driving the adoption of the pneumococcal vaccines.
The route of administration is the lane by which a vaccine is brought into contact with the body. Vaccines are administered through Intramuscular (IM), Subcutaneous (SC/SQ), oral, and others (intradermal and nasal). In 2017, the intramuscular accounted for the largest share of the of the global vaccines market. The large share of this segment is mainly due to availability of wide range of vaccines for IM.
Subunit, recombinant, polysaccharide, and conjugate vaccines accounted for the largest share of the global vaccines market in 2017. The large share of this segment is mainly attributed to increasing focus of companies towards recombinant and conjugate vaccines, growing prevalence of diseases, and increasing government initiatives.
An in-depth analysis of the geographical scenario of the industry provides detailed qualitative and quantitative insights about the five major geographies (North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa) along with the coverage of major countries in each region.
North America accounted for largest share of vaccines market in 2017. The large share of this segment is mainly attributed to the well established vaccination program in the region, increasing prevalence of diseases, growing adoption of advanced vaccines, and large pool of key players.
The Asia-Pacific vaccines market is expected to grow at a highest CAGR of 8.9%. The growth in the APAC market is mainly attributed to large patient pool, rising prevalence of diseases, growing awareness on vaccination, increasing government initiatives, and expanding presence of key players in this region. In addition, factors such as increasing disposable income and growing awareness about heath in emerging countries are further propelling the demand of vaccines in APAC.*Key Topics Covered:**1. Introduction*
1.1. Market Definition
1.2. Market Segmentation
1.3. Currency and Limitations
1.4. Key Stakeholders
*2. Research Methodology*
2.1. Research Process
2.1.1. Secondary Research
2.1.2. Primary Research
2.1.3. Market Size Estimation
*3. Executive Summary*
3.1. Introduction
3.2. Market Dynamics
3.3. Product Segment Analysis
3.4. Regional Market Analysis
3.5. Competitive Analysis
*4. Market Insights*
4.1. Market Overview
4.2. Market Dynamics
4.3. Drivers
4.3.1. Strong Vaccines Pipeline
4.3.2. Rising Adoption of Vaccination
4.3.3. Increasing Government Focus on Immunization Programs
4.3.4. Technological Progress in Vaccine Administration
4.4. Restraints
4.4.1. High Cost Associated with Vaccine Development
4.4.2. Longer Timelines for Vaccine Manufacturing
4.5. Opportunities
4.5.1. Increasing Epidemic Potentials
4.5.2. Growing Focus on Therapeutic Vaccines
4.5.3. Growth Prospects in Emerging Markets
4.5.4. Increasing Use of Adjuvants in Vaccines
4.6. Challenges
4.6.1. Product Recalls
4.6.2. Inadequate Access to Vaccines
*5. Industry Analysis*
5.1. Regulatory Analysis
5.2. Pipeline Analysis
5.3. Unmet Needs Analysis
5.4. Pricing Analysis, by Region
*6. Global Vaccines Market, by Indication*
6.1. Overview
6.2. Pneumococcal Disease
6.3. Influenza
6.4. DTP
6.5. Human Papilloma Virus (HPV)
6.6. Meningococcal Disease
6.7. Poliomyelitis (Polio)
6.8. MMR
6.9. Rotavirus
6.10. Hepatitis
6.11. Others
*7. Global Vaccines Market, by Route of Administration*
7.1. Overview
7.2. Intramuscular (IM)
7.3. Subcutaneous (SC)
7.4. Oral
7.5. Other (Routes of Administration)
*8. Global Vaccines Market, by Type/Antigen*
8.1. Overview
8.2. Subunit & Conjugate Vaccines
8.3. Inactivated Vaccines
8.4. Live Attenuated Vaccines
8.5. Toxoid Vaccines
*9. Global Vaccines Market, by Valence*
9.1. Overview
9.2. Multivalent Vaccines
9.3. Monovalent Vaccines
*10. Vaccines Market, by Region*
10.1. Overview
10.2. North America
10.2.1. U.S.
10.2.2. Canada
10.3. Europe
10.3.1. U.K.
10.3.2. Germany
10.3.3. France
10.3.4. Italy
10.3.5. Spain
10.3.6. Rest of Europe
10.4. Asia Pacific
10.4.1. China
10.4.2. Japan
10.4.3. India
10.4.4. Rest of Asia Pacific
10.5. Latin America
10.6. Middle East & Africa
*11. Competitive Landscape*
11.1. Overview
11.2. Competition Matrix
11.3. Market Share Analysis
11.3.1. Market Share Analysis, by Company
11.3.2. Market Share Analysis, by Product
*12. Company Profiles*
12.1. Sanofi Pasteur
12.2. Merck & Co., Inc.
12.3. GlaxoSmithKline Plc
12.4. Pfizer, Inc.
12.5. Johnson & Johnson
12.6. Daiichi Sankyo
12.7. Takeda Pharmaceutical Co. Ltd.
12.8. CSL Limited
12.9. Emergent BioSolutions Inc.
12.10. AstraZenecaFor more information about this report visit https://www.researchandmarkets.com/research/wk2zpk/global_57_5?w=12
Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.
CONTACT:
CONTACT: ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics: Gastrointestinal Drugs , Vaccines, Cancer Vaccines, Liver and Kidney Disorders Drugs Reported by GlobeNewswire 1 hour ago.
↧
Global $243.7 Billion Flexible Packaging Market, 2023 - The Proliferation of Bio-Based Plastic Films Imply a Promising Growth for the Flexible Packaging Materials
Dublin, Dec. 12, 2018 (GLOBE NEWSWIRE) -- The "Flexible Packaging Market By Material (Plastics, Paper, Aluminum Foil, Bioplastics), Design Type (Stand-Up Pouch, Spouted Pouch, Gusseted Bags, Rollstocks, Blisters, Wraps) - Global Opportunity Analysis And Industry Forecast To 2023" report has been added to *ResearchAndMarkets.com's* offering.Global flexible packaging market is expected to reach USD 243.7 billion by 2023, at a CAGR of 3.7% in the forecast period from 2018
The growth of this market is mainly driven by factors such as downgauging of plastic films, shift from traditional rigid packaging to flexible packaging, easy transportation and storage along with sustainable properties, increasing consumer focus on convenience and sustainability, and improving barrier properties.Also, the introduction of specialty films in the packaging industry, proliferation of bio-based plastics films, emerging markets, falling crude oil prices, and shift in food service from frozen to map packaged products will further fuel the growth of flexible packaging market. However, stringent government regulations and increasing raw material prices restrict the growth of this market to some extent.
The report gives an extensive outlook on various industries/facilities served by the flexible packaging providers. These industries include food and beverage, pharmaceuticals, household and personal care, tobacco products, industrial and chemical products, and oil and lubricants.
An in-depth analysis of the geographical scenario of the industry provides detailed qualitative and quantitative insights about the five major geographies (North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa) along with the coverage of major countries in each region. The geographic analysis provides detailed insights on the key trends of the industry in the listed regions & countries, identifying the demographic & economic impact, government & private investments, and regulatory scenario. The report identifies Asia-Pacific being the largest market followed by North America, Europe, and Rest of World. The geographical analysis section also comments on the key market players shaping the growth of the industry in the respective countries.
The report also includes the competitive landscape based on extensive assessment of the key strategic developments adopted by leading market participants in the industry over the past 4 years (2015-2018). The market players employed various strategies to expand their product offerings, global footprint, and augment their market share. The key strategies followed by most companies in the global flexible packaging market include agreements, partnerships, & collaborations; new product launches; mergers & acquisitions; and expansion.*Key Topics Covered:**1. Introduction*
1.1. Market Ecosystem
1.2. Currency and Limitations
1.3. Key Stakeholders
*2. Research Methodology*
2.1. Research Process
2.1.1. Secondary Research
2.1.2. Primary Research
2.1.3. Market Size Estimation
*3. Executive Summary*
*4. Market Insights*
4.1. Introduction
4.2. Drivers
4.2.1. Downgauging of Plastic Films
4.2.2. Shift from Traditional Rigid Packaging to Flexible Packaging
4.2.3. Increasing Consumer Focus on Convenience and Sustainability
4.2.4. Growing Food Losses and Wastes
4.2.5. Improving Barrier Properties
4.3. Restraints
4.3.1. Stringent Government Regulations
4.3.2. Increasing Raw Material Prices
4.4. Opportunities
4.4.1. Growing Adoption of Specialty Films
4.4.2. The Proliferation of Bio-Based Plastic Films Imply a Promising Growth for the Flexible Packaging Materials
4.4.3. Shift in Food Service from Frozen to Map Packaged Products
4.4.4. Falling Crude Oil Prices
4.4.5. Emerging Markets
4.5. Challenges
4.5.1. Inefficient Filling System
4.5.2. Recyclability
4.6. Market Share Analysis, by Key Players
4.7. Industry Composition-Supply Chain
*5. Global Flexible Packaging Market, by Material Type*
5.1. Introduction
5.2. Plastics
5.2.1. Polyethylene (PE)
5.2.2. Polypropylene (PP)
5.2.3. Polyethylene Terephthalate (PET)
5.2.4. Polyvinyl-Chloride (PVC)
5.2.5. Polystyrene (PS)
5.2.6. Others
5.3. Paper
5.4. Aluminum Foil
5.5. Bioplastics
5.6. Recycled Cellulose Fiber
*6. Global Flexible Packaging Market, by Design Type*
6.1. Introduction
6.2. Pouches
6.2.1. Standup Pouches
6.2.2. Flat Pouches
6.2.3. Spouted Pouches
6.3. Bags and Trays
6.3.1. Gusseted Bags
6.3.2. Wicketed Bags
6.4. Rollstocks
6.5. Squeezable Bottles
6.6. Blisters
6.7. Wraps
*7. Global Flexible Packaging Market, by Industry Vertical*
7.1. Introduction
7.2. Food and Beverages
7.3. Medical and Pharmaceuticals
7.4. Home & Personal Care
7.5. Tobacco Products
7.6. Industrial & Chemical Products
7.7. Oil & Lubricants
*8. Global Flexible Packaging Market, by Geography*
8.1. Introduction
8.2. North America
8.2.1. U.S.
8.2.2. Canada
8.2.3. Mexico
8.3. Europe
8.3.1. Germany
8.3.2. France
8.3.3. U.K.
8.3.4. Italy
8.3.5. Spain
8.3.6. Rest of Europe
8.4. Asia-Pacific
8.4.1. China
8.4.2. India
8.4.3. Australia
8.4.4. Japan
8.4.5. Rest of Asia-Pacific
8.5. Rest of World
8.5.1. Latin America
8.5.2. Middle-East and Africa
*9. Competitive Landscape*
9.1. Introduction
9.2. Alliance and Acquisitions
9.3. New Product Launches
9.4. Partnerships, Agreements, and Collaborations
9.5. Expansion
*10.Company Profiles*· Amcor Limited
· Bemis Company Inc.
· Berry Plastics Inc.
· Clondalkin Group Holdings BV
· Constantia Flexibles Group GmbH
· Coveris Holdings S.A.
· Huhtamaki Group
· Mondi Group
· Reynolds Group Holdings Limited
· Sealed Air Corporation
· Sonoco Products Company
For more information about this report visit https://www.researchandmarkets.com/research/684sbm/global_243_7?w=12
Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.
CONTACT:
CONTACT: ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics: Plastic Packaging , Paper and Board Packaging , Bioplastics Reported by GlobeNewswire 1 hour ago.
The growth of this market is mainly driven by factors such as downgauging of plastic films, shift from traditional rigid packaging to flexible packaging, easy transportation and storage along with sustainable properties, increasing consumer focus on convenience and sustainability, and improving barrier properties.Also, the introduction of specialty films in the packaging industry, proliferation of bio-based plastics films, emerging markets, falling crude oil prices, and shift in food service from frozen to map packaged products will further fuel the growth of flexible packaging market. However, stringent government regulations and increasing raw material prices restrict the growth of this market to some extent.
The report gives an extensive outlook on various industries/facilities served by the flexible packaging providers. These industries include food and beverage, pharmaceuticals, household and personal care, tobacco products, industrial and chemical products, and oil and lubricants.
An in-depth analysis of the geographical scenario of the industry provides detailed qualitative and quantitative insights about the five major geographies (North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa) along with the coverage of major countries in each region. The geographic analysis provides detailed insights on the key trends of the industry in the listed regions & countries, identifying the demographic & economic impact, government & private investments, and regulatory scenario. The report identifies Asia-Pacific being the largest market followed by North America, Europe, and Rest of World. The geographical analysis section also comments on the key market players shaping the growth of the industry in the respective countries.
The report also includes the competitive landscape based on extensive assessment of the key strategic developments adopted by leading market participants in the industry over the past 4 years (2015-2018). The market players employed various strategies to expand their product offerings, global footprint, and augment their market share. The key strategies followed by most companies in the global flexible packaging market include agreements, partnerships, & collaborations; new product launches; mergers & acquisitions; and expansion.*Key Topics Covered:**1. Introduction*
1.1. Market Ecosystem
1.2. Currency and Limitations
1.3. Key Stakeholders
*2. Research Methodology*
2.1. Research Process
2.1.1. Secondary Research
2.1.2. Primary Research
2.1.3. Market Size Estimation
*3. Executive Summary*
*4. Market Insights*
4.1. Introduction
4.2. Drivers
4.2.1. Downgauging of Plastic Films
4.2.2. Shift from Traditional Rigid Packaging to Flexible Packaging
4.2.3. Increasing Consumer Focus on Convenience and Sustainability
4.2.4. Growing Food Losses and Wastes
4.2.5. Improving Barrier Properties
4.3. Restraints
4.3.1. Stringent Government Regulations
4.3.2. Increasing Raw Material Prices
4.4. Opportunities
4.4.1. Growing Adoption of Specialty Films
4.4.2. The Proliferation of Bio-Based Plastic Films Imply a Promising Growth for the Flexible Packaging Materials
4.4.3. Shift in Food Service from Frozen to Map Packaged Products
4.4.4. Falling Crude Oil Prices
4.4.5. Emerging Markets
4.5. Challenges
4.5.1. Inefficient Filling System
4.5.2. Recyclability
4.6. Market Share Analysis, by Key Players
4.7. Industry Composition-Supply Chain
*5. Global Flexible Packaging Market, by Material Type*
5.1. Introduction
5.2. Plastics
5.2.1. Polyethylene (PE)
5.2.2. Polypropylene (PP)
5.2.3. Polyethylene Terephthalate (PET)
5.2.4. Polyvinyl-Chloride (PVC)
5.2.5. Polystyrene (PS)
5.2.6. Others
5.3. Paper
5.4. Aluminum Foil
5.5. Bioplastics
5.6. Recycled Cellulose Fiber
*6. Global Flexible Packaging Market, by Design Type*
6.1. Introduction
6.2. Pouches
6.2.1. Standup Pouches
6.2.2. Flat Pouches
6.2.3. Spouted Pouches
6.3. Bags and Trays
6.3.1. Gusseted Bags
6.3.2. Wicketed Bags
6.4. Rollstocks
6.5. Squeezable Bottles
6.6. Blisters
6.7. Wraps
*7. Global Flexible Packaging Market, by Industry Vertical*
7.1. Introduction
7.2. Food and Beverages
7.3. Medical and Pharmaceuticals
7.4. Home & Personal Care
7.5. Tobacco Products
7.6. Industrial & Chemical Products
7.7. Oil & Lubricants
*8. Global Flexible Packaging Market, by Geography*
8.1. Introduction
8.2. North America
8.2.1. U.S.
8.2.2. Canada
8.2.3. Mexico
8.3. Europe
8.3.1. Germany
8.3.2. France
8.3.3. U.K.
8.3.4. Italy
8.3.5. Spain
8.3.6. Rest of Europe
8.4. Asia-Pacific
8.4.1. China
8.4.2. India
8.4.3. Australia
8.4.4. Japan
8.4.5. Rest of Asia-Pacific
8.5. Rest of World
8.5.1. Latin America
8.5.2. Middle-East and Africa
*9. Competitive Landscape*
9.1. Introduction
9.2. Alliance and Acquisitions
9.3. New Product Launches
9.4. Partnerships, Agreements, and Collaborations
9.5. Expansion
*10.Company Profiles*· Amcor Limited
· Bemis Company Inc.
· Berry Plastics Inc.
· Clondalkin Group Holdings BV
· Constantia Flexibles Group GmbH
· Coveris Holdings S.A.
· Huhtamaki Group
· Mondi Group
· Reynolds Group Holdings Limited
· Sealed Air Corporation
· Sonoco Products Company
For more information about this report visit https://www.researchandmarkets.com/research/684sbm/global_243_7?w=12
Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.
CONTACT:
CONTACT: ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics: Plastic Packaging , Paper and Board Packaging , Bioplastics Reported by GlobeNewswire 1 hour ago.
↧
↧
Global Cell Culture Market to 2024 - Increasing Life Science Research, Increasing Prevalence of Chronic Diseases & Growing Demand for the Biopharmaceuticals Driving Market Growth
Dublin, Dec. 12, 2018 (GLOBE NEWSWIRE) -- The "Cell Culture Market By Product (Consumables, Equipment), Application (Biopharmaceutical, Cancer, Stem Cell), & End User (Pharma, Research) - Global Forecast To 2024" report has been added to *ResearchAndMarkets.com's* offering.*Global cell culture market is expected to reach $11,180.2 million by 2024, at a CAGR of 9.4% in the forecast period from 2018 to 2024*
The increase in life science research, growing prevalence of various chronic and infectious diseases, and growing demand for the biopharmaceuticals are the principal factors driving the growth of the global cell culture market. However, factors such as the high cost of cell culture research may hinder the market growth.
The report gives an extensive outlook on various industries/facilities served by the cell culture consumables and equipment. These industries include pharmaceuticals and biotechnology industry, academic and research institutes, and diagnostic laboratories. Apart from end users, the report provides insights on adoption of cell culture consumables and equipment in various application segments of the market.
An in-depth analysis of the geographic scenario of the industry provides detailed qualitative and quantitative insights about the five major geographies (North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa) along with the coverage of major countries in each region. The geographic analysis provides detailed insights on the key trends of the industry in the listed regions & countries, identifying the demographic & economic impact, government & private investments, and regulatory scenario. The report identifies North America being the largest market followed by Europe, Asia Pacific, and Rest of World. The geographic analysis section also comments on the key market players shaping the growth of the industry in the respective countries.
The report also includes the competitive landscape based on extensive assessment of the key strategic developments adopted by leading market participants in the industry over the past 4 years (2015-2018). The market players employed various strategies to expand their product offerings, global footprint, and augment their market shares. The key strategies followed by most companies in the global cell culture market include agreements, collaborations, new product launches, acquisitions, and expansions.*Key Topics Covered:**1. Introduction*
1.1. Market Ecosystem
1.2. Currency and Limitations
1.3. Key Stakeholders
*2. Research Methodology*
2.1. Research Process
2.1.1. Secondary Research
2.1.2. Primary Research
2.1.3. Market Size Estimation
*3. Executive Summary*
*4. Market Insights*
4.1. Introduction
4.2. Drivers
4.2.1. Increasing Life Science Research
4.2.2. Increasing Prevalence of Chronic Diseases
4.2.3. Growing Demand for the Biopharmaceuticals
4.3. Restraints
4.3.1. High Cost of Cell Culture Research
4.4. Challenge
4.4.1. Handling and Optimization of Protocol for In Vitro Study
4.5. Trend
4.5.1. Transition from Animal-Based Diagnosis to In-Vitro Cell-Based Diagnosis
*5. Cell Culture Market, by Product*
5.1. Introduction
5.2. Consumables
5.2.1. Media
5.2.1.1. Cell Culture Media Market, by Physical form
5.2.1.1.1. Dry Powder Media
5.2.1.1.2. Liquid Media
5.2.1.2. Cell Culture Media Market, by Type
5.2.1.2.1. Off-The-Shelf Media
5.2.1.2.2. Custom Media
5.2.1.3. Cell Culture Media Market, by Source
5.2.1.3.1. Chemically Defined Media
5.2.1.3.2. Natural Media
5.2.2. Reagents
5.2.2.1. Growth Factors and Cytokines
5.2.2.2. Cryoprotective Reagents
5.2.2.3. Antibiotics/ Antimycotics
5.2.2.4. Cell Dissociation Reagents
5.2.2.5. Buffers
5.2.2.6. Balanced Salt Solutions
5.2.2.7. Attachment and Matrix Factors
5.2.2.8. Other Cell Culture Reagents
5.2.3. Cells and Cell Lines
5.2.4. Sera
5.2.4.1. Fetal Bovine Serum
5.2.4.2. Other Sera
5.2.5. Cell Culture Vessels
5.2.5.1. Cell Culture Dishes
5.2.5.2. Cell Culture Plates
5.2.5.3. Cell Culture Flasks
5.2.5.4. Roller Bottles
5.2.5.5. Other Cell Culture Vessels
5.3. Equipment
5.3.1. Cryopreservative Containers
5.3.2. Refrigerators and Freezers
5.3.3. Biosafety Cabinets
5.3.4. Incubators
5.3.5. Sterilizers
5.3.6. Bioreactors
5.3.7. Microscopes
5.3.8. Centrifuges
5.3.9. Cell Counters
5.3.9.1 Automated Cell Counter
5.3.9.2 Haemocytometers
5.3.10. Water Baths
5.3.11. Other Equipment
*6. Cell Culture Market, by Application*
6.1. Introduction
6.2. Bioproduction
6.2.1. Monoclonal Antibody Production
6.2.2. Therapeutic Protein Production
6.2.3. Vaccine Production
6.2.4. Cell and Gene therapy
6.3. Diagnostics
6.4. Cancer Research
6.5. Drug Screening and Development
6.6. Stem Cell Research
*7. Cell Culture Market, by End-User*
7.1. Introduction
7.2. Pharmaceutical and Biotechnology Companies
7.3. Academic and Research Institutes
7.4. Diagnostic Laboratories
*8. Cell Culture Market, by Geography*
8.1. Introduction
8.2. North America
8.2.1. U.S.
8.2.2. Canada
8.3. Europe
8.3.1. Germany
8.3.2. Italy
8.3.3. France
8.3.4. U.K.
8.3.5. Spain
8.3.6. Rest of Europe
8.4. Asia-Pacific
8.4.1. Japan
8.4.2. India
8.4.3. China
8.4.4. Rest of Asia-Pacific
8.5. Rest of World
8.5.1. Latin America
8.5.2. Middle East and Africa
*9. Competitive Landscape*
9.1. Competitive Benchmarking
*10. Company Profiles*
10.1. HiMedia Laboratories
10.1.1. Business Overview
10.1.2. Financial Overview
10.1.3. Product Portfolio
10.1.4. Strategic Developments
10.2. Merck Group
10.3. GE Healthcare
10.4. Agilent Technologies, Inc.
10.5. Thermo Fisher Scientific Inc.
10.6. PromoCell GmbH
10.7. Lonza
10.8. Corning Inc.
10.9. Becton Dickinson
10.10. CellGenix GmbH
10.11. InvivoGen
10.12. Sartorius AG
10.13. Eppendorf AG
10.14. Fujifilm Holdings CorporationFor more information about this report visit https://www.researchandmarkets.com/research/kd9sch/global_cell?w=12
Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.
CONTACT:
CONTACT: ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics: Pharmaceuticals, Biopharmaceuticals , Stem Cells Reported by GlobeNewswire 1 hour ago.
The increase in life science research, growing prevalence of various chronic and infectious diseases, and growing demand for the biopharmaceuticals are the principal factors driving the growth of the global cell culture market. However, factors such as the high cost of cell culture research may hinder the market growth.
The report gives an extensive outlook on various industries/facilities served by the cell culture consumables and equipment. These industries include pharmaceuticals and biotechnology industry, academic and research institutes, and diagnostic laboratories. Apart from end users, the report provides insights on adoption of cell culture consumables and equipment in various application segments of the market.
An in-depth analysis of the geographic scenario of the industry provides detailed qualitative and quantitative insights about the five major geographies (North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa) along with the coverage of major countries in each region. The geographic analysis provides detailed insights on the key trends of the industry in the listed regions & countries, identifying the demographic & economic impact, government & private investments, and regulatory scenario. The report identifies North America being the largest market followed by Europe, Asia Pacific, and Rest of World. The geographic analysis section also comments on the key market players shaping the growth of the industry in the respective countries.
The report also includes the competitive landscape based on extensive assessment of the key strategic developments adopted by leading market participants in the industry over the past 4 years (2015-2018). The market players employed various strategies to expand their product offerings, global footprint, and augment their market shares. The key strategies followed by most companies in the global cell culture market include agreements, collaborations, new product launches, acquisitions, and expansions.*Key Topics Covered:**1. Introduction*
1.1. Market Ecosystem
1.2. Currency and Limitations
1.3. Key Stakeholders
*2. Research Methodology*
2.1. Research Process
2.1.1. Secondary Research
2.1.2. Primary Research
2.1.3. Market Size Estimation
*3. Executive Summary*
*4. Market Insights*
4.1. Introduction
4.2. Drivers
4.2.1. Increasing Life Science Research
4.2.2. Increasing Prevalence of Chronic Diseases
4.2.3. Growing Demand for the Biopharmaceuticals
4.3. Restraints
4.3.1. High Cost of Cell Culture Research
4.4. Challenge
4.4.1. Handling and Optimization of Protocol for In Vitro Study
4.5. Trend
4.5.1. Transition from Animal-Based Diagnosis to In-Vitro Cell-Based Diagnosis
*5. Cell Culture Market, by Product*
5.1. Introduction
5.2. Consumables
5.2.1. Media
5.2.1.1. Cell Culture Media Market, by Physical form
5.2.1.1.1. Dry Powder Media
5.2.1.1.2. Liquid Media
5.2.1.2. Cell Culture Media Market, by Type
5.2.1.2.1. Off-The-Shelf Media
5.2.1.2.2. Custom Media
5.2.1.3. Cell Culture Media Market, by Source
5.2.1.3.1. Chemically Defined Media
5.2.1.3.2. Natural Media
5.2.2. Reagents
5.2.2.1. Growth Factors and Cytokines
5.2.2.2. Cryoprotective Reagents
5.2.2.3. Antibiotics/ Antimycotics
5.2.2.4. Cell Dissociation Reagents
5.2.2.5. Buffers
5.2.2.6. Balanced Salt Solutions
5.2.2.7. Attachment and Matrix Factors
5.2.2.8. Other Cell Culture Reagents
5.2.3. Cells and Cell Lines
5.2.4. Sera
5.2.4.1. Fetal Bovine Serum
5.2.4.2. Other Sera
5.2.5. Cell Culture Vessels
5.2.5.1. Cell Culture Dishes
5.2.5.2. Cell Culture Plates
5.2.5.3. Cell Culture Flasks
5.2.5.4. Roller Bottles
5.2.5.5. Other Cell Culture Vessels
5.3. Equipment
5.3.1. Cryopreservative Containers
5.3.2. Refrigerators and Freezers
5.3.3. Biosafety Cabinets
5.3.4. Incubators
5.3.5. Sterilizers
5.3.6. Bioreactors
5.3.7. Microscopes
5.3.8. Centrifuges
5.3.9. Cell Counters
5.3.9.1 Automated Cell Counter
5.3.9.2 Haemocytometers
5.3.10. Water Baths
5.3.11. Other Equipment
*6. Cell Culture Market, by Application*
6.1. Introduction
6.2. Bioproduction
6.2.1. Monoclonal Antibody Production
6.2.2. Therapeutic Protein Production
6.2.3. Vaccine Production
6.2.4. Cell and Gene therapy
6.3. Diagnostics
6.4. Cancer Research
6.5. Drug Screening and Development
6.6. Stem Cell Research
*7. Cell Culture Market, by End-User*
7.1. Introduction
7.2. Pharmaceutical and Biotechnology Companies
7.3. Academic and Research Institutes
7.4. Diagnostic Laboratories
*8. Cell Culture Market, by Geography*
8.1. Introduction
8.2. North America
8.2.1. U.S.
8.2.2. Canada
8.3. Europe
8.3.1. Germany
8.3.2. Italy
8.3.3. France
8.3.4. U.K.
8.3.5. Spain
8.3.6. Rest of Europe
8.4. Asia-Pacific
8.4.1. Japan
8.4.2. India
8.4.3. China
8.4.4. Rest of Asia-Pacific
8.5. Rest of World
8.5.1. Latin America
8.5.2. Middle East and Africa
*9. Competitive Landscape*
9.1. Competitive Benchmarking
*10. Company Profiles*
10.1. HiMedia Laboratories
10.1.1. Business Overview
10.1.2. Financial Overview
10.1.3. Product Portfolio
10.1.4. Strategic Developments
10.2. Merck Group
10.3. GE Healthcare
10.4. Agilent Technologies, Inc.
10.5. Thermo Fisher Scientific Inc.
10.6. PromoCell GmbH
10.7. Lonza
10.8. Corning Inc.
10.9. Becton Dickinson
10.10. CellGenix GmbH
10.11. InvivoGen
10.12. Sartorius AG
10.13. Eppendorf AG
10.14. Fujifilm Holdings CorporationFor more information about this report visit https://www.researchandmarkets.com/research/kd9sch/global_cell?w=12
Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.
CONTACT:
CONTACT: ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics: Pharmaceuticals, Biopharmaceuticals , Stem Cells Reported by GlobeNewswire 1 hour ago.
↧
Amazon Web Services opens Swedish datacenters, its first in the Nordics
Amazon’s cloud computing industry, Amazon Internet Services and products (AWS), has formally opened its first cloud area within the Nordics. AWS first published plans to open datacenters in Sweden in April remaining yr, and it has met its 2018 goal with a couple of weeks to spare. The area, which is known as AWS Europe …
Reported by The News Articles 58 minutes ago.
↧
JAGGAER, Science Exchange and OvaScience Cite Supply Chain Digital Transformation as Critical for R&D Efficiency in 2019
RESEARCH TRIANGLE PARK, N.C., Dec. 12, 2018 (GLOBE NEWSWIRE) -- The key to accelerating the R&D process for research-intensive companies, like biopharma, lies in a clear strategy and adoption of technologies for digital transformation, argue Elizabeth Iorns, Ph.D., CEO of Science Exchange, Inc., James Lillie, Ph.D., Chief Scientific Officer at OvaScience, Inc., and Nancy McLaughlin, Director, Professional Services at JAGGAER, on the latest edition of JAGGAER’s InsideSpend webinar series. JAGGAER is the world’s largest independent spend management company, Science Exchange is the leading marketplace for research services, and OvaScience is a publicly traded biotechnology company. This webinar was designed to provide actionable insights for Chief Procurement Officers, VPs, and Directors and Managers of procurement.Webinar Link.
As cited by the Wall Street Journal, the average cost of bringing a new drug to market is $2.4B over 10 years, with a high failure rate. The key to accelerating the process, driving down costs, and managing risk, lies in digital transformation of the supporting supply chain. A successful digital supply chain integrates multiple technologies for managing procurement, inventory, contracts, and suppliers. New online R&D marketplaces, such as Science Exchange, offer specific solutions for research-intensive companies, such as the R&D organization led by James Lillie, Ph.D., to better manage R&D services.
“We're seeing a big shift in our industry from internal R&D to external R&D services. It's impossible really to build all these diverse and evolving capabilities and expertise you would need, so you have to access expert and efficient external providers of R&D services,” observes Lillie.
“Over 50% of R&D budgets for pharmaceutical and biotech companies are spent with external partners,” adds Elizabeth Iorns, Ph.D. “When you’re thinking of a Source-to-Pay mechanism, the most expensive and riskiest components of that procurement process actually lie in the services part of the business. And most companies actually don’t have any good infrastructure to support this.”
JAGGAER’s Nancy McLaughlin described additional components required for digital transformation of R&D. “Digital tools to manage EHS and other security requirements remove time-consuming manual processes, eliminate the risk associated with dated inventory, and provide the data and insights to understand and control all externally procured assets.”
Understanding the components of a digital transformation, the cost savings and efficiencies created, and the necessity to make the move in 2019 are just some of the topics explored in this important JAGGAER webinar.
Webinar Link.
*About JAGGAER: Global Source to Pay Spend Management Solutions *
JAGGAER is the world’s largest independent spend management company, with nearly 2,000 customers connected to a network of 3.7 million suppliers in 70 countries, served by offices located in North America, Latin America, throughout Europe, the United Kingdom, Australia, Asia, and the Middle East. JAGGAER offers complete SaaS-based Source to Pay eProcurement solutions with advanced Spend Analytics, Sourcing, Supplier Management, Contract Lifecycle Management, Savings Tracking, and intelligent workflow capabilities. JAGGAER has pioneered spend solutions for over two decades and continues to lead the innovation curve by listening to customers and analyzing the market. Our solution suites are trusted by the world’s largest manufacturing, education, health care, retail, consumer packaged goods, logistics, construction, utilities companies and public service organizations. Additionally, JAGGAER holds 38 patents–more than any other spend management company. www.JAGGAER.com
To join the conversation, please visit our blog at https://JAGGAER.com/blog/ or follow us on Twitter @JaggaerPro*MEDIA CONTACT:
JAGGEAR: *
news@JAGGAER.com
919-659-2601 Reported by GlobeNewswire 1 hour ago.
As cited by the Wall Street Journal, the average cost of bringing a new drug to market is $2.4B over 10 years, with a high failure rate. The key to accelerating the process, driving down costs, and managing risk, lies in digital transformation of the supporting supply chain. A successful digital supply chain integrates multiple technologies for managing procurement, inventory, contracts, and suppliers. New online R&D marketplaces, such as Science Exchange, offer specific solutions for research-intensive companies, such as the R&D organization led by James Lillie, Ph.D., to better manage R&D services.
“We're seeing a big shift in our industry from internal R&D to external R&D services. It's impossible really to build all these diverse and evolving capabilities and expertise you would need, so you have to access expert and efficient external providers of R&D services,” observes Lillie.
“Over 50% of R&D budgets for pharmaceutical and biotech companies are spent with external partners,” adds Elizabeth Iorns, Ph.D. “When you’re thinking of a Source-to-Pay mechanism, the most expensive and riskiest components of that procurement process actually lie in the services part of the business. And most companies actually don’t have any good infrastructure to support this.”
JAGGAER’s Nancy McLaughlin described additional components required for digital transformation of R&D. “Digital tools to manage EHS and other security requirements remove time-consuming manual processes, eliminate the risk associated with dated inventory, and provide the data and insights to understand and control all externally procured assets.”
Understanding the components of a digital transformation, the cost savings and efficiencies created, and the necessity to make the move in 2019 are just some of the topics explored in this important JAGGAER webinar.
Webinar Link.
*About JAGGAER: Global Source to Pay Spend Management Solutions *
JAGGAER is the world’s largest independent spend management company, with nearly 2,000 customers connected to a network of 3.7 million suppliers in 70 countries, served by offices located in North America, Latin America, throughout Europe, the United Kingdom, Australia, Asia, and the Middle East. JAGGAER offers complete SaaS-based Source to Pay eProcurement solutions with advanced Spend Analytics, Sourcing, Supplier Management, Contract Lifecycle Management, Savings Tracking, and intelligent workflow capabilities. JAGGAER has pioneered spend solutions for over two decades and continues to lead the innovation curve by listening to customers and analyzing the market. Our solution suites are trusted by the world’s largest manufacturing, education, health care, retail, consumer packaged goods, logistics, construction, utilities companies and public service organizations. Additionally, JAGGAER holds 38 patents–more than any other spend management company. www.JAGGAER.com
To join the conversation, please visit our blog at https://JAGGAER.com/blog/ or follow us on Twitter @JaggaerPro*MEDIA CONTACT:
JAGGEAR: *
news@JAGGAER.com
919-659-2601 Reported by GlobeNewswire 1 hour ago.
↧
More Pages to Explore .....
